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A B S T R A C T
Background
Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 (known as
HER2-positive) or not (HER2-negative). Typically, patients with HER2-positive disease have a worse prognosis. Trastuzumab is a
selective treatment that targets theHER2pathway. The available evidence supporting trastuzumab regimensmostly relies upon surrogate
endpoints and, although the efficacy results seem to support its use, other uncertainties have been raised about its net benefit in relation
to transient cardiac toxicity and a long-term increased risk of metastasis to the central nervous system.
Objectives
To assess the evidence on the efficacy and safety of therapy with trastuzumab (overall) and in relation to the type of co-administered
regimen and the line of treatment, i.e. first-line or beyond progression, in women with HER2-positive metastatic breast cancer.
Search methods
We searched the Cochrane Breast Cancer Group’s (CBCG) Specialised Register and used the search strategy developed by the CBCG to
search for randomised controlled trials (RCTs) in CENTRAL (2013, Issue 1), MEDLINE, EMBASE, BIOSIS, theWHO International
Clinical Trials Registry Platform (ICTRP) search portal and ClinicalTrials.gov (up to 17 January 2013).
Selection criteria
RCTs comparing the efficacy and safety of trastuzumab alone or in combination with chemotherapy, hormonal therapy or targeted
agents in women with HER2-positive metastatic breast cancer.
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Data collection and analysis
We collected data from published trials. We used hazard ratios (HRs) for time-to-event outcomes and risk ratio (RRs) for binary
outcomes. Subgroup analyses included type of regimen (taxane-containing, anthracycline-containing, aromatase inhibitor-containing
or other) and treatment line (first-line, beyond progression).
Main results
The review found seven trials, involving 1497 patients, which met the criteria to be included. The trials were generally of moderate
methodological quality; two studies have not published their results on overall survival so the presence of selective outcome reporting bias
cannot be ruled out.None of the studies used blinding to treatment allocation, though this is unlikely to have biased the results for overall
survival. Studies varied in terms of co-administered regimen and in terms of treatment line. In four studies, trastuzumabwas administered
with a chemotherapy, such as a taxane-containing, anthracycline-containing or capecitabine-containing regimen. Two studies considered
postmenopausal women and administered trastuzumab with hormone-blocking medications, such as an aromatase inhibitor. One study
administered trastuzumab in addition to lapatinib. Five studies out of seven included women treated with trastuzumab administered
until progression as first-line treatment and two studies considered trastuzumab beyond progression. The combined HRs for overall
survival and progression-free survival favoured the trastuzumab-containing regimens (HR 0.82, 95% confidence interval (CI) 0.71 to
0.94, P = 0.004; and HR 0.61, 95% CI 0.54 to 0.70, P < 0.00001, respectively; moderate-quality evidence). Trastuzumab increased
the risk of congestive heart failure (RR 3.49, 90% CI 1.88 to 6.47, P = 0.0009; moderate-quality evidence) and left ventricular ejection
fraction (LVEF) decline (RR 2.65, 90% CI 1.48 to 4.74, P = 0.006). For haematological toxicities, such as neutropenic fever and
anaemia, there was no clear evidence that risks differed between groups, while trastuzumab seemed to raise the risk of neutropenia.
The overall survival improvement was maintained when considering patients treated as first-line or patients receiving taxane-based
regimens. The progression-free survival improvement was maintained when considering patients receiving taxane-based regimens, and
patients treated as first-line or subsequent lines. Few data were collected on central nervous system progression. Similarly, few studies
reported on quality of life and treatment-related deaths.
Authors’ conclusions
Trastuzumab improved overall survival and progression-free survival in HER2-positive women with metastatic breast cancer, but it also
increased the risk of cardiac toxicities, such as congestive heart failure and LVEF decline. The available subgroup analyses are limited
by the small number of studies. Studies that administered trastuzumab as first-line treatment, or along with a taxane-based regimen,
improved mortality outcomes. The evidence to support the use of trastuzumab beyond progression is limited. The recruitment in three
out of seven studies was stopped early and in three trials more than 50% of patients in the control groups were permitted to switch to
the trastuzumab arms at progression, making it more difficult to understand the real net benefit of trastuzumab.
Trastuzumab is generally used for women with HER2-positive early breast cancer in clinical practice, while women enrolled in most
of the trials in the metastatic setting were naive to trastuzumab. The effectiveness of trastuzumab for women relapsing after adjuvant
trastuzumab is therefore still an open issue, although it is likely that the majority are being offered it again.
P L A I N L A N G U A G E S U M M A R Y
Efficacy and safety of trastuzumab in metastatic breast cancer
Tumours characterised by the presence of the HER2 protein are found in about one in five women with metastatic breast cancer. These
tend to be more aggressive and the prognosis and choice of treatment are affected. Trastuzumab (Herceptin®) is a targeted biological
drug (a monoclonal antibody) that attaches to the HER2 protein, blocking the growth of malignant cells.
We included seven trials with 1497 women who had HER2-positive metastatic breast cancer in this review. They were assigned by
chance to receive trastuzumab with or without chemotherapy (taxane, anthracycline or capecitabine in four studies), hormonal therapy
(aromatase inhibitors including letrozole or anastrozole in two studies) or targeted therapy (lapatinib in one study). Women treated
with trastuzumab were followed up until disease progression in five studies and beyond disease progression in two studies. The length
of trastuzumab administration varied between 8.7 and 30 months, and follow-up averaged two years after starting trastuzumab.
All studies found that trastuzumab extends time to disease progression, with gains varying between two and 11 months, and in five
studies it extended time to death by between five and eight months. However, some patients develop severe heart toxicity (congestive
heart failure) during treatment. While trastuzumab reduces breast cancer mortality by one-fifth, the risk of heart toxicity is between
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three and four times more likely. If 1000 women were given standard therapy alone (with no trastuzumab) about 300 would survive and
10 would have heart toxicities. With the addition of trastuzumab to this treatment, an additional 73 would have their lives prolonged,
and an additional 25 would have severe heart toxicity. Omitting the anthracycline-trastuzumab arms (which would not be regarded as
standard of care) 21 patients would have severe heart toxicity (11 more than the chemotherapy alone group). These heart toxicities are
often reversible if the treatment is stopped once heart disease is discovered. Women with advanced disease might choose to accept this
risk. On balance, this review shows that with trastuzumab the time to disease progression and survival benefits outweigh the risk of
heart harm.
Trastuzumab does not increase the risk of haematological toxicities, such as neutropenic fever and anaemia; however, it seems to raise
the risk of neutropenia. There were insufficient data on the impact of trastuzumab on quality of life, treatment-related deaths and brain
metastases to reach a conclusion for these outcomes.
We rated the overall quality of the evidence as moderate, with the main weaknesses being the fact that all studies included were open-
label (not blinded), which may have affected the outcome assessments for time to disease progression and toxicities, and that two studies
have not published their results for mortality. Furthermore, the recruitment in three out of seven studies was stopped early and in three
trials more than 50% of patients in the control groups were permitted to switch to the trastuzumab arms at disease progression, making
it more difficult to understand the real net benefit of trastuzumab on mortality. The evidence to support the use of trastuzumab beyond
disease progression is limited.
It is important to highlight that, although trastuzumab is used for women with HER2-positive early breast cancer, the women enrolled
in these metastatic trials were not previously treated with trastuzumab. The effectiveness of trastuzumab for women relapsing after
adjuvant trastuzumab is still an open issue, although it is likely that it is offered to the majority of them.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Summary of findings for the main comparison. Overview: efficacy and safety outcomes for patient groups at different risks
Patient or population: patients with HER2-positive metastatic breast cancer
Settings: metastatic breast cancer
Intervention: trastuzumab
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Trastuzumab
Overall survival
Follow-up: median 2
years
Moderate1 HR 0.82
(0.71 to 0.94)
1309
(5 studies)
⊕⊕⊕©
moderate2
700 per 1000 627 per 1000
(575 to 678)
High1
800 per 1000 733 per 1000
(681 to 780)
Progression-free sur-
vival
Follow-up: median 2
years
Moderate HR 0.61
(0.54 to 0.70)
1489
(7 studies)
⊕⊕⊕©
moderate3
700 per 1000 520 per 1000
(478 to 569)
High
800 per 1000 625 per 1000
(581 to 676)
Congestive heart failure Low RR 3.49
(1.88 to 6.47)4
1459
(7 studies)
⊕⊕⊕©
moderate3
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10 per 1000 35 per 1000
(19 to 65)
Moderate
20 per 1000 70 per 1000
(38 to 129)
High
50 per 1000 175 per 1000
(94 to 323)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; HR: hazard ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Moderate risk derived from Slamon 2001 first-line treatment. High risk: estimated from moderate risk increased by 10% absolute risk.
2Gasparini 2006, Huober 2012 and von Minckwitz 2009 did not report the overall survival data stratified by arm.
3All the studies were open-label.
4Confidence interval 90%.
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B A C K G R O U N D
Description of the condition
Breast cancer is the most commonly diagnosed cancer in women
(Ferlay 2010), and the second leading cause of cancer-related
death. Patients with breast cancer are classified as having cells
that over-express the human epidermal growth factor receptor 2
(known as HER2-positive) or not (HER2-negative). The gene en-
coding the HER2 is amplified and the protein is over-expressed
in 20% to 25% of women with metastatic breast cancer (Slamon
1987). Patients with HER2-positive disease typically have a worse
prognosis (Gschwind 2004).
Description of the intervention
The antibody trastuzumab (Herceptin®) was developed as a
means of blocking the tyrosine kinase-linked human epidermal
growth factor receptor-2 (HER2) (Coussens 1985). The study
by Baselga et al provided the first clinical evidence of the an-
titumour activity of this recombinant human monoclonal anti-
body against HER2 in patients with HER2 over-expressing breast
carcinomas (Baselga 1996). Research by Baselga et al and other
follow-up studies have documented an important difference be-
tween trastuzumab and most standard chemotherapy agents due
to its tolerability, with a favourable risk-benefit profile in patients
with metastatic breast cancer (Cobleigh 1999; Vogel 2001). The
most common adverse events are fever, chills and other acute
and self limiting symptoms that may accompany the initial infu-
sion of trastuzumab. Cardiac dysfunction has been reported with
trastuzumab, particularly when used in combination with anthra-
cycline-based chemotherapy, but many patients will recover with
standard treatment for congestive heart failure (Seidman 2002).
Furthermore, it has been observed that patients with HER2 over-
expressing metastatic breast cancer receiving trastuzumab are at
an increased risk for isolated central nervous system progression
(Burstein 2005; Pestalozzi 2006), possibly because they are living
longer with improved systemic disease control.
Why it is important to do this review
Due to reported improvements in time to disease progression and
survival, the US Food and Drug Administration rapidly approved
trastuzumab in 1998 for the treatment of women with metastatic
breast cancer (FDA 1998). Other drug regulatory agencies ap-
proved trastuzumab following a longer period of scrutiny of the
evidence - the UK National Institute for Health and Clinical
Excellence recommended trastuzumab for women with HER2-
positive advanced breast cancer in 2002 (NICE 2002). The evi-
dence supporting trastuzumab regimens mostly relied upon sur-
rogate endpoints (e.g. progression-free survival). The strength of
this evidence has been questioned (Apolone 2005; Joppi 2005),
and other uncertainties have been raised about the net benefit of
trastuzumab, particularly related to transient cardiac toxicity and
secondly to a long-term increased risk of metastasis to the central
nervous system.
The purpose of this review is to systematically evaluate the evi-
dence for the efficacy and safety of the use of trastuzumab alone
or in combination with chemotherapy in women with metastatic
breast cancer using evidence from randomised controlled trials.
We recognise that since some of the adverse events of interest are
rare but serious, and occur during long-term use of trastuzumab,
we need to look also at non-randomised studies to address our
question fully. We plan to carry out a systematic review of non-
randomised studies as a second phase of this project.
O B J E C T I V E S
To assess the evidence on the efficacy and safety of therapy with
trastuzumab (overall) and in relation to the type of co-adminis-
tered regimen and the line of treatment, i.e. first-line or beyond
progression, in women with HER2-positive metastatic breast can-
cer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Women with HER2-positive metastatic breast cancer, of any age,
menopausal status or hormone receptor status.
Types of interventions
1. Intervention group: trastuzumab alone or in combination
with chemotherapy, hormonal therapy or targeted agents.
2. Comparator: the same regimen used in the intervention
group without trastuzumab.
Trials could include both women with metastatic disease and
women with locally advanced/recurrent disease, as long as the data
on the patients with metastatic disease could be extracted from the
data reported.
Trials could or could not specify recommended treatment upon
disease progression or initial treatment failure. We included trials
where patients crossed over to the other treatment arm at the time
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of progression or received other treatment off-study in this review,
and analysed these according to the treatment they were originally
randomised to receive.
Types of outcome measures
Primary outcomes
• Overall survival on intention-to-treat analysis.
• Progression-free survival.
Secondary outcomes
• Overall response rate.
• Cardiac toxicity per protocol analysis (all patients who
received the experimental treatment, regardless of compliance).
• Other toxicities (defined and graded according to the
World health Organization (WHO)/National Cancer Institute
(NCI) toxicity Criteria.
• Recurrence in central nervous system.
• Treatment-related deaths.
• Quality of life.
We applied the following definitions of the outcomes:
• Overall survival: time from randomisation to death (from
any cause).
• Progression-free survival: time from randomisation to date
of progression or death (from any cause). We considered time to
progression (TTP - time from randomisation to date of
progression) when progression-free survival was not reported.
• Overall response rate: the proportion of patients with a
complete or partial response. Partial response is defined as a
decrease in the size of a tumour, or in the extent of cancer in the
body, in response to treatment.
• Cardiac toxicity: congestive heart failure and decline of left
ventricular ejection fraction (LVEF). We considered the
following definitions of congestive heart failure: cardiac
dysfunction New York Heart Association class III-IV; severe,
symptomatic or confirmed congestive heart failure. The decline
of LVEF was defined as reported by the authors, as different
thresholds were used.
• Other toxicities: neutropenic fever (grade 3/4),; anaemia
(grade 3/4) and neutropenia (grade 3/4).
• Recurrence in central nervous system (CNS): the
proportion of patients with disease progression due to metastases
to CNS. Time to recurrence (also referred to as disease-free
interval): time from date randomised to date of first CNS
recurrence. Isolated metastasis to CNS confirmed radiologically
by computed tomography (CT) or magnetic resonance imaging
(MRI) scanning in patients with new brain or leptomeningeal
metastasis.
• Treatment-related death is defined as death due to drug
toxicity not due to disease progression, reported as ’treatment-
related’, ’toxic death’ or ’lethal toxicity’.
• Quality of life: expression of well-being, measured through
a validated scale (i.e. SF-36, European Organisation for Research
and Treatment of Cancer (EORTC), Functional Assessment of
Cancer Therapy (FACT)).
Search methods for identification of studies
We limited our search to articles published after 1 January 1996;
this is the date when Baselga and colleagues first presented data
on the efficacy of trastuzumab in humans (Baselga 1996).
Electronic searches
For RCTs, see: Cochrane Breast Cancer Group search strat-
egy (http://www.mrw.interscience.wiley.com/cochrane/clabout/
articles/BREASTCA/frame.html).
We searched the following databases:
1. Cochrane Breast Cancer Group (CBCG) Specialised
Register on 14 January 2013. Details of the search strategy
applied to create the register and the procedure used to code
references are described in the Group’s module in The Cochrane
Library. The register includes both published and unpublished
trials (including ongoing). We applied the CBCG codes
’advanced’ and ’immunotherapy’ to the Specialised Register and
combined with the following keywords (imported with the
references from MEDLINE): ’trastuzumab’ [Substance Name],
and a search of all non-indexed fields for the following text
words: Trastuzumab, Herceptin or monoclonal antibod* AND
HER2.
2. Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library) on 17 January 2013 (Issue
1). See Appendix 1 for the search strategy;
3. MEDLINE (via OVID) (searched on 17 January 2013).
Refer to Appendix 2.
4. EMBASE (via EMBASE.com) (searched on 17 January
2013). Refer to Appendix 3.
5. WHO International Clinical Trials Registry Platform
(ICTRP) search portal (http://apps.who.int/trialsearch/
AdvSearch.aspx), for all prospectively registered and ongoing
trials (searched on 17 January 2013). Refer to Appendix 4).
6. ClinicalTrials.gov (http://www.clinicaltrials.gov/) (searched
on 23 January 2013). Refer to Appendix 5.
7. BIOSIS (host: ISI Web of Knowledge), January 1996 to
current (searched on 23 January 2013). Refer to Appendix 6.
We used the medical subject headings ’Breast Neoplasms’, ’An-
tineoplastic Agents’, ’Adverse effects’ and ’Toxicity’, and the text
words ’Trastuzumab’, ’Herceptin’, ’Adverse effect’, ’Side effect’,
’Toxic effect’, ’Drug toxicity’, ’Drug tolerance’, ’Causality’, ’Risk’,
’Adverse event’, ’Adverse drug reaction’, ’Breast cancer’, ’Breast tu-
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mour’, ’Breast tumor’ and ’Breast neoplasm’. We included reports
irrespective of the language in which they were reported.
Searching other resources
We searched the Health Technology Assessment (HTA) Database
and the Database of Abstracts of Reviews of Effects (DARE) to
identify existing systematic reviews. We scanned the lists of studies
included in these systematic reviews to assemble a list of known
RCTs.
Data collection and analysis
The methods of this systematic review partially overlap with
another Cochrane review exploring the efficacy and safety of
trastuzumab in early breast cancer (Moja 2012).
Selection of studies
Three review authors (SB, SM and LT) independently screened
the titles and abstracts of articles that were found for inclusion. We
also assessed information available from conference proceedings
on unpublished studies. We resolved disagreements by discussion.
We obtained a copy of the full article for each reference reporting
a potentially eligible trial. We sought further information from
the authors where papers contained insufficient information to
make a decision about eligibility. We applied the selection criteria
described above to each trial. We recorded reasons for exclusion.
We entered the characteristics and outcomes of the included trials,
and details of the excluded trials, into our database.
Data extraction and management
Three review authors (SB, SM and LT) independently extracted
information from the included trials using the pro-forma process
piloted on a random sample of papers investigating other chemo-
therapy agents. Another review author (LM) checked data for cor-
rectness. We recorded details of study design, participants, setting,
interventions, follow-up, quality components, efficacy outcomes
and side effects. The extraction form is available from the review
authors upon request. We also recorded details of previous thera-
pies given to patients (including endocrine or other therapy). For
studies with more than one publication, we extracted data from all
of the publications. However, we considered the final or updated
version of each trial to be the primary reference for efficacy and
toxicity unless otherwise specified (i.e. a large part of the included
patients crossed over to the other treatment arm during follow-
up). We included trials where patients crossed over to the other
treatment arm at the time of progression, or received the other
treatment off-study and weremanaged according to the armwhere
they were originally randomised.
Assessment of risk of bias in included studies
We based the ’Risk of bias’ assessment on the data provided in
the publications included. If a study was reported in more than
one publication, we used the publication with the most complete
reporting.
Randomised controlled trials
We classified the generation of allocation sequence, allocation con-
cealment, completeness of outcome data and selective outcome
reporting as ’adequate’ (low risk of bias), ’inadequate’ (high risk of
bias) or ’unclear’ following the criteria specified in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Three review authors (SB, SM and LT) independently assessed
trials according to the predefined quality criteria. Another review
author (LM) checked data for correctness. We evaluated the im-
pact of methodological quality only on the primary outcomes by
considering the allocation concealment item.
We assessed the overall quality of evidence using the GRADE ap-
proach (Guyatt 2008). The GRADE approach appraises the qual-
ity of a body of evidence based on the extent to which one can be
confident that an estimate of effect or association reflects the item
being assessed. Randomised trials start as high-quality evidence,
but may be downgraded due to: risk of bias (methodological qual-
ity), indirectness of evidence, unexplained heterogeneity, impreci-
sion (sparse data) and publication bias. We determined the overall
quality of the evidence for each outcome after considering each of
these factors and judged this as follows.
• High: further research is very unlikely to change our
confidence in the estimate of effect.
• Moderate: further research is likely to have an important
impact on our confidence in the estimate of effect and may
change the estimate.
• Low: further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate.
• Very low: any estimate of effect is very uncertain.
Quality assessment for observational studies
In future updates of this review, we will separately assess the
methodological quality of observational studies by using a compo-
nent approach considering: concurrent, concomitant treatment;
how allocation occurred; any attempt to balance groups by design;
blinding of outcome assessment; completeness of follow-up; iden-
tification of prognostic factors (e.g. cardiovascular risk factors) and
case-mix adjustment. These components are part of a list of qual-
ity items identified through a systematic review of the literature
(Deeks 2003). We will not assess the quality of case series or single
case reports.
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Measures of treatment effect
Survival-type outcomes
The measure of association chosen for overall survival and pro-
gression-free survival was the hazard ratio (HR). A HR less than
1.0 favoured regimens containing trastuzumab and ratios larger
than 1.0 favoured regimens that do not contain trastuzumab.
Dichotomous outcomes
The measure of association chosen for combining overall re-
sponse rate and toxicities was the risk ratio (RR). For overall re-
sponse rate, a RR greater than 1.0 favoured regimens containing
trastuzumab, and less than 1.0 favoured regimens that do not con-
tain trastuzumab. For toxicities, a RR greater than 1.0 indicated
that the experimental treatment was more toxic than the control,
and less than 1.0 suggested that the control was more toxic than
the experimental treatment.
Dealing with missing data
Where possible, we sought anymissingdata or unclear information
using the Internet, by contacting the authors and by checking for
the best available resource or publication.
Assessment of heterogeneity
We assessed heterogeneity using the Chi2 test and the I2 statistic
(Higgins 2011). The I2 statistic indicates the percentage of the
overall variability that is due to between-study (or inter-study) vari-
ability, as opposed to within-study (or intra-study) variability. We
assumed that latent clinical heterogeneity was ubiquitous, there-
fore we combined the studies using the random-effects model, re-
gardless of statistical evidence for heterogeneity in the effect sizes.
We classified an I2 value greater than 50% as having substantial
heterogeneity and discussed this accordingly (Higgins 2011).
Assessment of reporting biases
We evaluated the risk of outcome reporting bias for overall sur-
vival and progression-free survival. In each study, we assessed the
absence of these outcomes and discussed its possible impact on
the overall estimates.
Data synthesis
We directly extracted the HRs and their variances for overall sur-
vival and progression-free survival from the papers. If not reported,
we indirectly obtained the HRs by using the methods described in
Parmar 1998, employing either other available summary statistics
or data extracted from published Kaplan-Meier curves.
For all adverse events and brain metastases, treated as binary data,
we used the RR as the measure of association and fixed a higher
type I error (α = 0.10, two-sided) (Shadish 2002).
We pooled the HRs and RRs on the log scale through the
generic inverse variance approach, using the random-effects model
(DerSimonian 1986).
Subgroup analysis and investigation of heterogeneity
We pre-specified two subgroup analyses:
1. analysis by type of regimen (anthracycline-based, taxane-
based, other chemotherapy-based, other targeted agents-based);
2. line of chemotherapy for metastatic breast cancer (first-line
versus other).
Sensitivity analysis
We conducted a sensitivity analysis in order to assess the impact of
methodological quality on the primary outcomes, i.e. overall sur-
vival and progression-free survival, by considering the allocation
concealment item.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Randomised trials evaluating the efficacy of the therapy with
trastuzumab in metastatic breast cancer therapy first started ac-
cruing patients in the early 1990s, as the first study on this topic
was published in 1996 (Baselga 1996). Since then, research has
rapidly moved forward on the treatment of metastatic and early
breast cancer with this drug, judging from the number of arti-
cles reporting results from randomised and observational trials in
PubMed. See Figure 1 for the results of the search strategy.
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Figure 1. Study flow diagram.
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Search results from MEDLINE, EMBASE, CENTRAL, the
CBCG’s Specialised Register, BIOSIS databases and trial registers
provided 7660 citations. After removing duplicates, there were
6407 citations remaining. Of these, we discarded 6368 after re-
viewing the titles and abstracts because they clearly did not meet
the inclusion criteria. We examined the full text of the remaining
39 citations: three references did not meet the inclusion criteria
(see: Characteristics of excluded studies) and we excluded 12 refer-
ences as we could not find the full text. Twenty-four publications
(corresponding to seven trials) met the inclusion criteria and we
included them in this systematic review.
Included studies
See: Characteristics of included studies.
We identified and defined seven eligible studies evaluating the effi-
cacy or safety of trastuzumab in patients with HER2-over-express-
ing metastatic breast cancer as RCTs (Slamon 2001; Marty 2005;
Gasparini 2006; Kaufman 2009; von Minckwitz 2009; Blackwell
2010; Huober 2012). All studies were fully published in peer-re-
viewed journals. For two trials additional unpublished data were
provided by the investigators or obtained from regulatory agency
reports or trial registries (Slamon 2001; Gasparini 2006).
The study by Slamon 2001 had four arms; two of them were
experimental (anthracyclines or taxane plus trastuzumab) and two
were control arms (anthracyclines or taxane alone). Data were
reported for all arms, allowing us to lump together the two arms in
which trastuzumab was administrated and the other two control
arms.
Characteristics of patients
The seven studies randomised a total of 1497 HER2-positive
women; 752womenwere allocated to the trastuzumab-containing
arm and 745 to the non-trastuzumab-containing arm. All studies
included women aged between 24 and 88 years and the reported
median ages ranged from 51 to 59 years.
Five studies enrolled untreated metastatic patients and excluded
those with brainmetastases (Slamon 2001;Marty 2005; Gasparini
2006;Kaufman2009;Huober 2012). Previous adjuvant treatment
with anthracyclines was permitted in Marty 2005 and Gasparini
2006. Gasparini 2006 also included patients previously treated
with taxanes. Kaufman 2009 considered eligible patients treated
with tamoxifen or anastrozole. Kaufman 2009, Slamon 2001 and
Huober 2012 did not clearly report the inclusion criteria with re-
spect to prior treatment with anthracyclines or taxanes. Huober
2012 enrolled postmenopausal women with newly diagnosed hor-
mone receptor (HR)-positive metastatic breast cancer or locally
advanced breast cancer; none of the patients in this trial received
aromatase inhibitors or trastuzumab in the adjuvant setting.
Two studies enrolled metastatic breast cancer patients who pro-
gressed during prior trastuzumab-based therapy (von Minckwitz
2009; Blackwell 2010). In the von Minckwitz trial, the median
duration of previous trastuzumab treatment was 45 weeks (range:
7 to 235 weeks) in the control arm and 44 weeks (range: 10 to
284 weeks) in the trastuzumab arm. In the trial by Blackwell, both
groups had received a median of three prior trastuzumab regimens
for metastatic disease. In the study by von Minckwitz, 3% of pa-
tients in the control arm and 1%of the patients in the trastuzumab
arm had central nervous system metastases. Blackwell 2010 did
not clearly report the inclusion criteria with respect to patients
with central nervous system metastases.
As an inclusion criterion all the trials required normal heart func-
tion, with the exception of Slamon 2001, although patients were
monitored for cardiac dysfunction.
Six RCTs included only HER2-positive patients (Slamon 2001;
Marty 2005; Gasparini 2006; Kaufman 2009; von Minckwitz
2009; Blackwell 2010). In the study byHuober, an amendment for
German sites permitted the implementation of a third arm where
patients with HER2-negative and HR-positive tumours were as-
signed to receive letrozole alone as first-line treatment (Huober
2012). We only considered the data from HER2-positive patients
for our analyses.
Interventions used in the trials
Five trials evaluated trastuzumab as first-line treatment and admin-
istered it until progression (Slamon 2001; Marty 2005; Gasparini
2006; Kaufman 2009; Huober 2012). Three trials combined
trastuzumab with a taxane (Slamon 2001; Marty 2005; Gasparini
2006). A second arm of Slamon 2001 combined trastuzumab with
an anthracycline plus cyclophosphamide. Kaufman 2009 used the
regimen of trastuzumab with anastrozole. Huober 2012 used the
regimen of trastuzumab with letrozole.
Two studies evaluated trastuzumab in patients with metastatic
breast cancer who progressed after treatment with trastuzumab
(von Minckwitz 2009; Blackwell 2010); von Minckwitz com-
bined trastuzumab with capecitabine while Blackwell combined
trastuzumab with lapatinib. In the von Minckwitz study, patients
could have received up to one chemotherapy drug for metastatic
disease: 4% of patients in the trastuzumab arm received first-line
treatment during the study; all the remaining included patients
received second-line treatment. Blackwell combined trastuzumab
in a heavily pretreated patient population (median number of
prior trastuzumab-based regimens: three). In this trial, patients
were randomised to receive either oral lapatinib 1500 mg daily or
oral lapatinib 1000 mg daily in combination with trastuzumab.
Although the treatment regimen in the control arm was not the
same as in the trastuzumab arm (i.e. a 30% relative increase in
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the lapatinib dose), we decided to include the study in the meta-
analysis and to exclude it in a sensitivity analysis.
In five studies the protocol prescribed trastuzumab at 2 mg/kg
weekly doses (with a loading dose of 4 mg/kg) (Slamon 2001;
Marty 2005; Gasparini 2006; Kaufman 2009; Blackwell 2010). In
the study by von Minckwitz 2009, trastuzumab was administered
at a dose of 6 mg/kg every three weeks (after a loading dose of
8 mg/kg). In the study by Huober 2012, the protocol prescribed
trastuzumab at 2 mg/kg weekly doses (with a loading dose of 4
mg/kg), but approximately two years after the start of the study
trastuzumab was allowed to be given as a three-weekly application
with a dose of 6 mg/kg (after a loading dose of 8 mg/kg).
Themedian number of doses of trastuzumab differed among stud-
ies: Slamon 2001 prescribed a median of 36 doses, Marty 2005
39 doses and Gasparini 2006 and Kaufman 2009 25 doses each;
for von Minckwitz 2009 the median number of doses was nine.
Blackwell 2010 and Huober 2012 did not clearly report informa-
tion on the number of administered doses.
All studies reported detailed safety data with details of toxicities
encountered in each arm.
Quality of life data were properly reported in two papers only,
referring to the studies by Slamon 2001 and von Minckwitz 2009
(see Osoba 2002 and Wu 2011 sub-references).
All the trials were funded by pharmaceutical companies.
Excluded studies
We excluded three studies as ineligible for the reasons reported in
Characteristics of excluded studies.
Risk of bias in included studies
See: Figure 2 (’Risk of bias’ summary table).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Since the trials were conducted at multiple sites, it is likely that
these trials had unbiased central randomisation procedures, pro-
tocol integrity and rigorous and reliable data registration, in order
to satisfy regulatory authorities and human investigation commit-
tees. We could not directly assess methodological quality because
details of the methods used (such as the mechanism of allocation
concealment) were not always provided in the published reports
or alternative presentations (i.e. meeting proceedings or regula-
tory agency reports). None of the studies used blinding to treat-
ment allocation, a common practice in phase III oncological tri-
als, because of the difficulty in concealing different infusion times,
schedules and toxicities. This was unlikely to bias the results of the
studies where overall survival was measured, as this outcome was
not subject to observer or patient bias in interpretation.
Allocation
All studies were described as randomised. We assessed the genera-
tion of a random sequence as adequate for three trials (Gasparini
2006; Kaufman 2009; von Minckwitz 2009); four studies did
not report sufficient details (Slamon 2001;Marty 2005; Blackwell
2010; Huober 2012). We assessed allocation concealment as ade-
quate in one trial (Gasparini 2006).
Treatment groups were well balanced in four studies (Slamon
2001; Gasparini 2006; Kaufman 2009; Blackwell 2010). Clini-
cally relevant imbalances were reported by:
• Marty 2005: compared to the trastuzumab group, the
control group had more patients with positive oestrogen and
progesterone receptors (56% versus 41%) and fewer patients
receiving prior adjuvant anthracyclines (55% versus 64%);
• Huober 2012: more patients in the control arm (71%) than
in the trastuzumab arm (42%) had received adjuvant systemic
treatment, and tamoxifen as adjuvant endocrine treatment was
given in 65% and 31% of patients, respectively;
• von Minckwitz 2009: T3-4 stage at first diagnosis was more
frequent in the capecitabine and trastuzumab arm than in the
capecitabine alone arm (respectively: 34% and 14%).
These imbalances may have introduced some biases in the esti-
mated intervention effect.
Blinding
All the studies were open-label, so performance bias cannot be
ruled out. Outcome assessment may be influenced by unblinded
investigators or patients. While overall survival is unlikely to be
influenced by a lack of blinding, open-label trials might be at
high risk of bias, particularly trials using subjective outcomes such
as quality of life or pain reduction. However, in trials testing
trastuzumab, outcomes were assessed by combining subjective and
objective dimensions: progression-free survival or congestive heart
failure were confirmed through imaging and biochemical tests.
The independence that these tests ensure from the investigator’s
subjective assessment is difficult to predict. We reasoned that the
risk of detection bias in open-label trials for progression-free sur-
vival, overall response rate and congestive heart failure was mar-
ginal: we decided to rate studies as having unclear risk of bias
for these outcomes. We suggest that trialists use central indepen-
dent adjudication committees to evaluate these outcomes inde-
pendently from the study site and completely blinded to the treat-
ment allocation of the patient. This would eliminate any subjec-
tive element from the outcome assessment, guaranteeing a low risk
of bias for outcome determination. Only Kaufman 2009 declared
that they relied upon a blinded Response Evaluation committee.
Incomplete outcome data
The rate of loss to follow-up was minimal (less than 3%) and ac-
counted for in all of the trials. In Blackwell 2010, although 26
patients (9%) had withdrawn consent or were lost to follow-up
before death, only eight patients (2.7%) were lost to follow-up be-
fore progression (progression-free survival is the primary outcome
of the study).
Selective reporting
The protocols for the studies were not available for Gasparini 2006
and Kaufman 2009.
At the moment, Gasparini 2006 and Huober 2012 have not pub-
lished or released their results for overall survival, therefore the
presence of selective outcome reporting bias cannot be ruled out.
Gasparini 2006 reported that the total number of deaths occur-
ring in both arms was 42, but they did not provide information
on how many patients died in the treatment and the control arms.
Huober 2012 reported that there was no significant difference in
overall survival between arms, without showing data. If the overall
survival data are released, we will include these data in the review
update. Kaufman 2009 reported results for the primary and sec-
ondary outcomes: it is likely that reporting bias has not occurred.
In the paper published in 2011, von Minckwitz 2009 reported
updated results only for overall survival.
Other potential sources of bias
Two trials were closed prematurely because of slow recruitment
(von Minckwitz 2009; Huober 2012). Another trial was stopped
early because data from other trials suggested that only pa-
tients with strong HER2 over-expression (3+) gain benefit from
trastuzumab (Gasparini 2006). Three trials allowed patients in
the control arm experiencing progression to cross over to the
trastuzumab arm: 52%, 56% and 57% of patients in the con-
trol arm crossed over to the experimental arm, respectively (Marty
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2005; Kaufman 2009; Blackwell 2010). Sixty-six per cent of the
patients in the Slamon 2001 trial, upon documented disease pro-
gression, were entered into the extension study H0659g, a non-
randomised, open-label study in which they could receive either
trastuzumab alone or in combination with a chemotherapy of
choice.
The possibility of switching from the control arm to the experi-
mental arm at progression makes it more difficult to interpret the
results for overall survival (Moja 2012).
Effects of interventions
See: Summary of findings for the main comparison
See: Summary of findings for the main comparison.
Efficacy of trastuzumab
Overall survival
Overall survival was reported in five out of the seven included trials
(Slamon2001;Marty 2005;Kaufman 2009; vonMinckwitz 2009;
Blackwell 2010). Trastuzumab extended time to death by between
five and eight months. We indirectly estimated the hazard ratio
(HR) for the Kaufman 2009 trial by using the number of events
occurring in each arm and the P value of the log-rank test. We
indirectly estimated the HR for theMarty 2005 trial as the ratio of
the medians for the time to death in the trastuzumab and control
groups; we estimated its variance by dividing the total number of
deaths by four, as suggested in Parmar 1998. For Blackwell 2010,
we considered the analysis that censored patient data at the time
of cross-over after progression, as reported in the paper published
in 2012. For the study by vonMinckwitz 2009, we considered the
data reported in the paper published in 2011, which focused on
overall survival: 119 deaths were observed.
Although each single study reported a non-statistically significant
difference between groups, our meta-analysis showed a statistically
significant improvement in overall survival among patients treated
with trastuzumab-containing regimens compared to the control
group (HR 0.82, 95% confidence interval (CI) 0.71 to 0.94, P =
0.004; Analysis 1.1). There was no heterogeneity among studies
(I2 = 0%). The results are reported in Figure 3 and in Summary
of findings for the main comparison.
Figure 3. Forest plot of comparison: 1 Efficacy of trastuzumab, outcome: 1.1 Overall survival - all studies.
We conducted a sensitivity analysis by excluding Blackwell 2010,
because the lapatinib dose was higher in the control arm compared
to the trastuzumab arm. The result did not change substantially
(HR 0.82, 95% CI 0.70 to 0.95, P = 0.009; Analysis 1.2).
Overall survival stratified by type of regimen
The taxane-containing regimen subgroup consisted of two studies
(Marty 2005 and the paclitaxel arms of Slamon 2001), while the
other subgroups included one study each: in the anthracycline-
containing regimen subgroup, there was the anthracycline arms
of Slamon 2001; in the aromatase inhibitor-containing regimen
subgroup, there was Kaufman 2009; and in the lapatinib-contain-
ing regimen subgroup, there was the study by Blackwell 2010.
The taxane-containing regimen reported a statistically significant
improvement in overall survival (HR 0.80, 95% CI 0.65 to 0.99,
P = 0.04; Analysis 1.3).
Overall survival stratified by treatment line
The studies that administered trastuzumab as first-line treatment
were Slamon 2001, Marty 2005 and Kaufman 2009. Blackwell
2010 and von Minckwitz 2009 considered trastuzumab beyond
progression. The analysis showed that trastuzumab as first-line
treatment improved overall survival (HR 0.79, 95% CI 0.67 to
0.94, P = 0.006; Analysis 1.4). The difference in overall survival
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did not reach statistical significance in the studies administering
trastuzumab beyond progression (P = 0.27). The test for differ-
ences between treatment line subgroups was not statistically sig-
nificant (P = 0.55). The results are reported in Figure 4.
Figure 4. Forest plot of comparison: 1 Efficacy of trastuzumab, outcome: 1.4 Overall survival - stratified by
treatment line.
Progression-free survival
Progression-free survival was provided by or estimated from all
seven included trials (Slamon 2001; Marty 2005; Gasparini 2006;
Kaufman 2009; von Minckwitz 2009; Blackwell 2010; Huober
2012). For Slamon 2001, Marty 2005 and Gasparini 2006 we
considered the time to progression. Although there were some dif-
ferences in the definitions of time to progression (i.e. not consid-
ering death as an event contributing to the composite outcome),
we judged these to have a minor impact on the overall analysis of
progression-free survival (in Marty 2005 and Slamon 2001), due
to the lack of heterogeneity between studies. Indeed we decided
to pool the data irrespective of the progression-free survival def-
inition adopted. Trastuzumab extended time to disease progres-
sion with gains varying between two and 11 months. We indi-
rectly estimated the HR for the Marty 2005 trial as the ratio of
the medians for the time to progression in the trastuzumab and
control groups; we estimated its variance by using the relationship
between theChi2 test and the logHR. It was not possible to report
the total number of progression-free survival events since Marty
2005 and Slamon 2001 did not report this basic information. For
the study by Blackwell 2010, we considered the intention-to-treat
(ITT) analysis reported in the paper published in 2012. The anal-
ysis showed a statistically significant improvement in progression-
free survival among patients treated with trastuzumab-containing
regimens compared to the control group (HR 0.61, 95% CI 0.54
to 0.70, P < 0.00001; Analysis 1.5). We found low heterogeneity
among studies (I2 =12%).The results are reported in the Summary
of findings for the main comparison.
The sensitivity analysis excluding Blackwell 2010 provided a very
similar benefit favouring trastuzumab (HR 0.58, 95% CI 0.50 to
0.66, P < 0.00001; Analysis 1.6).
Progression-free survival stratified by type of regimen
The taxane-containing regimen subgroup was composed of three
studies (the paclitaxel arms of Slamon 2001, Marty 2005 and
Gasparini 2006), with a significant difference in progression-free
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survival (HR 0.53, 95% CI 0.42 to 0.68). In the anthracycline-
containing regimen subgroup there were the anthracycline arms
of Slamon 2001, with a significant improvement in progression-
free survival (HR 0.78, 95% CI 0.68 to 0.91). In the subgroup
who received aromatase inhibitor-containing regimens, the pooled
hazard ratio for the Huober 2012 and Kaufman 2009 trials was
statistically significant (HR 0.64, 95% CI 0.49 to 0.83). In the
subgroup who received other types of regimens, the pooled hazard
ratio for the Blackwell 2010 and von Minckwitz 2009 trials was
statistically significant (HR 0.72, 95% CI 0.59 to 0.88). Hetero-
geneity was not detected among studies in each subgroup (I2 =
0%). The variability among subgroups was high (I2 = 60.8%).
Refer to Analysis 1.7 for these results.
Progression-free survival stratified by treatment line
The studies that administered trastuzumab as first-line treatment
were Slamon 2001, Marty 2005, Gasparini 2006, Kaufman 2009
and Huober 2012. von Minckwitz 2009 and Blackwell 2010 con-
sidered trastuzumab beyond progression. The analysis showed
that trastuzumab significantly improved progression-free survival,
both as first-line treatment (HR 0.56, 95% CI 0.49 to 0.65, P
< 0.00001) and beyond progression (HR 0.72, 95% CI 0.59 to
0.88, P = 0.001). No heterogeneity was found among studies in
each subgroup (I2 = 0%). As expected, the test for differences be-
tween treatment line subgroups showed that trastuzumab seems to
be more effective as first-line treatment compared to beyond pro-
gression (P = 0.04). The results are reported in Figure 5 (Analysis
1.8).
Figure 5. Forest plot of comparison: 1 Efficacy of trastuzumab, outcome: 1.8 Progression-free survival -
stratified by treatment line.
Overall response rate
The seven included trials reported information on overall response
rates (Slamon 2001; Marty 2005; von Minckwitz 2009; Huober
2012 according to ITT analysis; Gasparini 2006; Kaufman 2009;
Blackwell 2010 according to per protocol analysis). There were
293 cases (41.3%) out of 710 in the trastuzumab group and 178
(25.1%) out of 709 in the control group who had an overall re-
sponse. The overall response rate was higher in patients treated
with trastuzumab (risk ratio (RR) 1.58, 95% CI 1.38 to 1.82, P
< 0.00001) (Analysis 1.9).
Overall response rate stratified by type of regimen
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The analysis showed an overall response rate favouring the
trastuzumab group for all subgroups. In the taxane-containing
groups, the RR was 1.71 (95% CI 1.23 to 2.38, P = 0.002). In
the anthracycline-containing groups, the RR was 1.33 (95% CI
1.04 to 1.70, P = 0.02). In the aromatase inhibitor-containing
groups, the RR was 2.55 (95% CI 1.23 to 5.27, P = 0.01). In
the subgroup that administered other types of regimens, the RR
was 1.70 (95% CI 1.16 to 2.49, P = 0.006). See Analysis 1.10 for
these results. There was no heterogeneity among studies in each
subgroup, with the exception of the taxane-containing subgroup
(substantial heterogeneity, I2 = 62%).
Overall response rate stratified by treatment line
The analysis showed that trastuzumab significantly improved over-
all response rate both as first-line treatment (RR 1.57, 95% CI
1.34 to 1.84, P < 0.00001) and beyond progression (RR 1.70,
95% CI 1.16 to 2.49, P = 0.006; see Analysis 1.11).We found low
heterogeneity among studies in the first-line subgroup (I2 = 5%);
we found no heterogeneity among studies in the beyond progres-
sion subgroup (I2 = 0%).
Safety of trastuzumab
Data on cardiac dysfunction were reported in different ways
among the included studies. We decided to combine data on ma-
jor cardiac toxicities (e.g. congestive heart failure and cardiac dys-
function NYHA class III and IV) under the outcome congestive
heart failure and to combine data on left ventricular ejection frac-
tion (LVEF) decline, considering definitions for relevant decline
as reported in the original study irrespective of the threshold used,
under the outcome LVEF decline.
Congestive heart failure
All seven included trials reported data on congestive heart fail-
ure or severe cardiac events, totaling 1459 patients with HER2-
positive metastatic breast cancer. Blackwell 2010 reported a fa-
tal cardiac event in the trastuzumab arm. From Gasparini 2006
two events were reported, one acute myocardial infarction oc-
curred in the control arm and one ischaemic heart attack occurred
in the trastuzumab arm. No symptomatic congestive heart fail-
ure was observed in Huober 2012. Kaufman 2009 reported one
grade 3 cardiac failure and one grade 4 myocardial ischaemia in
the trastuzumab arm, while one grade 3 sinus tachycardia and
one grade 4 myocardial ischaemia occurred in the control arm.
Marty 2005 reported two symptomatic congestive heart failures
in the trastuzumab arm. Slamon 2001 observed cardiac dysfunc-
tion NYHA class III/IV in 25 in the trastuzumab arms and five
in the control arms. In von Minckwitz 2009, four patients in the
trastuzumab arm experienced severe cardiac events.
There were 35 cases (4.7%) of severe cardiac event out of 738 in
the trastuzumab group and 8/721 (1.1%) in the control group.
The overall result indicated an increased risk of severe cardiac event
with trastuzumab (RR 3.49, 90% CI 1.88 to 6.47, P = 0.0009;
Analysis 2.1).We detected no heterogeneity (I2 = 0%). The results
are reported in Figure 6 and in Summary of findings for the main
comparison.
Figure 6. Forest plot of comparison: 2 Cardiac toxicity of trastuzumab, outcome: 2.1 Congestive heart
failure - all studies.
Congestive heart failure stratified by type of regimen
Based on two arms in Slamon 2001, trastuzumab in combination
with an anthracycline significantly increased the risk of a severe
cardiac event compared with an anthracycline alone (RR 5.43,
90% CI 2.28 to 12.94, P = 0.001). There was a trend for such
an increase for the taxane-containing regimens (RR 1.98, 90% CI
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0.54 to 7.26, P = 0.39) and in the subgroup of studies administer-
ing other types of regimens (RR 5.31, 90% CI 0.87 to 32.20, P
= 0.13), with the possible exception of those including aromatase
inhibitors (RR 1.01, 90% CI 0.20 to 5.15, P = 0.99). Where ap-
plicable, we found no heterogeneity among studies in each sub-
group (I2 = 0%). The test for subgroup differences showed that
the observed cardiotoxicity does not depend on type of regimen
used (P = 0.40). Excluding from the analysis the anthracycline-
containing arms of Slamon 2001, the RR failed to reach statistical
significance (RR 2.06, 90%CI 0.85 to 4.99, P = 0.18). The results
are likely to be influenced by the low number of events observed in
most subgroups and differences between regimens have not been
ruled out. Refer to Analysis 2.2.
Congestive heart failure stratified by treatment line
Trastuzumab as first-line treatment seemed to significantly increase
the risk of a severe cardiac event (RR 3.30, 90%CI 1.71 to 6.37, P
= 0.003). We observed a larger increase in the subgroup of studies
which administered trastuzumab beyond progression (RR 5.31,
90% CI 0.87 to 32.20, P = 0.13), although it did not reach the
threshold for statistical significance. We found no heterogeneity
among studies in each subgroup (I2 = 0%). The test for subgroup
differences showed that the observed cardiotoxicity does not de-
pend on the treatment line (P = 0.68). Refer to Analysis 2.3.
Decline in left ventricular ejection fraction
Data on decline in LVEF could be extracted from six trials (Marty
2005; Gasparini 2006; Kaufman 2009; von Minckwitz 2009;
Blackwell 2010; Huober 2012). Blackwell 2010 observed 10
events of grade≥ 3 left ventricular systolic dysfunction or decrease
in LVEF ≥ 20% relative to the baseline value and below the nor-
mal lower limit (as defined by the institution) in the trastuzumab
arm and three such events in the control arm. Kaufman 2009 ob-
served one confirmed decrease of ≥ 15 LVEF percentage points
from baseline to < 50% in the trastuzumab arm. In the study by
von Minckwitz 2009, a decrease in LVEF to less than 40% (or by
greater than 10% from baseline) was observed in one patient in
the trastuzumab group. No cases of significant decrease in LVEF
occurred in Gasparini 2006. Huober 2012 observed a mean de-
crease of 3% for patients in the control arm and of 7% in the
trastuzumab arm. The different reporting meant that we could
not include the data from Huober 2012 in the pooled analysis.
Based on five trials (Marty 2005; Gasparini 2006; Kaufman 2009;
vonMinckwitz 2009; Blackwell 2010), there were 28 cases (5.9%)
of LVEF decline out of 478 women in the trastuzumab group and
nine (2.0%) out of 460 in the control group. The pooled analysis
indicated an increased risk of decline in LVEF with trastuzumab
(RR 2.65, 90% CI 1.48 to 4.74, P = 0.006; Analysis 2.4). No
heterogeneity was detected (I2 = 0%).
Decline in left ventricular ejection fraction stratified by type
of regimen
The analyses for the taxane-containing subgroups and the other
regimens (that is capecitabine and lapatinib) showed a statistically
significant increase in the risk of LVEF decline (respectively RR
2.36, 90% CI 1.12 to 4.96, P = 0.06; RR 3.21, 90% CI 1.19
to 8.64, P = 0.05). The results are inconclusive for the aromatase
inhibitor-containing subgroup (RR3.03, 90%CI 0.21 to 44.02, P
=0.50). The results are likely to be influencedby the lownumber of
events observed inmost subgroups.Where applicable, we observed
no heterogeneity (I2 = 0%). Refer to Analysis 2.5.
Decline in left ventricular ejection fraction stratified by
treatment line
Trastuzumab seemed to increase the risk of LVEF decline both as
first-line treatment and administered beyond progression (respec-
tively RR 2.40, 90% CI 1.17 to 4.91, P = 0.04; RR 3.21, 90% CI
1.19 to 8.64, P = 0.05; Analysis 2.6). We found no heterogeneity
among studies in both subgroups (I2 = 0%).
Other toxicities
Neutropenic fever
Three studies reported information on neutropenic fever (Marty
2005; Gasparini 2006; vonMinckwitz 2009). There were 24 cases
(10.3%) out of 232 in the trastuzumab group and 17 (7.5%) out
of 228 in the control group. The increased risk of neutropenic
fever in patients treated with trastuzumab was not statistically
significant (RR 1.38, 90% CI 0.86 to 2.21, P = 0.26; Analysis
3.1). We detected no heterogeneity (I2 = 0%).
Neutropenic fever stratified by type of regimen/treatment line
A low number of studies reported data on neutropenic fever, there-
fore the subgroup analysis by type of regimen and the subgroup
analysis by treatment line were the same. The subgroup com-
posed of Gasparini 2006 and Marty 2005, which administered
trastuzumab along with a taxane-containing regimen and as first-
line treatment, reported an increased risk of neutropenic fever
which failed to reach statistical significance (RR1.32, 90%CI 0.82
to 2.13, P = 0.34). In von Minckwitz 2009, which administered
trastuzumab along with capecitabine and beyond progression, a
non-significant increased risk of neutropenic fever was observed
(RR 4.81, 90% CI 0.38 to 60.61, P = 0.31). Where applicable,
we found no heterogeneity (I2 = 0%). Refer to Analysis 3.2 and
Analysis 3.3.
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Anaemia
Four studies reported information on anaemia (Slamon 2001;
Marty 2005; Gasparini 2006; von Minckwitz 2009). No events
occurred in Gasparini 2006. There were six cases (1.3%) out of
466 in the trastuzumab group and seven (1.5%) out of 458 in
the control group. There was no evidence of an increased risk of
anaemia in patients treated with trastuzumab (RR 0.93, 90% CI
0.37 to 2.35, P = 0.90) (Analysis 3.4). We observed no hetero-
geneity (I2 = 0%).
Anaemia stratified by type of regimen
There was no evidence of an increased risk of developing anaemia
in any of the subgroups defined by different regimens. For the
taxane-containing regimen, the RR was 1.03 (90% CI 0.20 to
5.30, P = 0.97). For the anthracycline-containing regimen, the RR
was 1.26 (90% CI 0.36 to 4.35, P = 0.76). For the subgroup of
studies administering other types of regimens, the RR was 0.19
(90% CI 0.02 to 2.42, P = 0.28). The results are likely to be
influencedby the lownumber of events observed in each subgroup.
Where applicable, there was no heterogeneity (I2 = 0%). Refer to
Analysis 3.5.
Anaemia stratified by treatment line
There was no evidence of an increased risk of anaemia in either
subgroup. For the first-line subgroup, the RR was 1.19 (90% CI
0.44 to 3.19, P = 0.77) and for the beyond progression subgroup,
the RR was 0.19 (90% CI 0.02 to 2.42, P = 0.28). Where appli-
cable, we found no heterogeneity (I2 = 0%). Refer to Analysis 3.6.
Neutropenia
Three studies reported information on neutropenia (Marty 2005;
Gasparini 2006; von Minckwitz 2009). There were 41 cases
(17.7%) out of 232 in the trastuzumab group and 28 (12.3%)
out of 228 in the control group. The increased risk of neutropenia
in patients treated with trastuzumab was of borderline statistical
significance (RR 1.46, 90% CI 1.02 to 2.08, P = 0.08; Analysis
3.7). We detected no heterogeneity (I2 = 0%).
Neutropenia stratified by type of regimen/treatment line
A low number of studies reported data on neutropenia, therefore
the subgroup analysis by type of regimen and the subgroup anal-
ysis by treatment line were the same. The subgroup composed by
Gasparini 2006 andMarty 2005,which administered trastuzumab
along with a taxane-containing regimen and as first-line treat-
ment, reported an increased risk of neutropenia of borderline sta-
tistical significance (RR 1.48, 90% CI 1.02 to 2.14, P = 0.09).
In von Minckwitz 2009, which administered trastuzumab along
with capecitabine and beyond progression, the observed increased
risk of neutropenia was not significant (RR 1.28, 90% CI 0.38 to
4.37, P = 0.74). Where applicable, we found no heterogeneity (I
2 = 0%). Refer to Analysis 3.8 (type of regimen) and Analysis 3.9
(treatment line).
Recurrence in central nervous system
One study reported information on brain metastases (Slamon
2001). Therewere 42 cases (17.9%) out of 235 in the trastuzumab-
containing group and 21/234 (9.0%) in the control group (RR
1.99, 95% CI 1.32 to 3.01). Blackwell 2010, which allowed the
accrual of patients with known brain metastases, reported that
nine (6.2%) out of the 146 patients treated with trastuzumab ex-
perienced central nervous system progression, whereas 15 patients
(10.3) out of the 145 treated with lapatinib alone experienced
progression while on study (RR 0.60, 90% CI 0.31 to 1.16). We
decided against pooling the data.
Treatment-related deaths
Slamon 2001 reported that two deaths, both in the trastuzumab
arm, were possibly related to the therapy. In the Marty 2005 trial,
two drug-related deaths occurred in the control arm. Blackwell
2010 reported that one patient died in the trastuzumab arm
with cardiac failure (concurrent with pulmonary thromboem-
bolism) considered to be treatment-related. No drug-related
deaths were observed in the Gasparini 2006, Kaufman 2009 and
von Minckwitz 2009 trials. Huober 2012 did not report data on
treatment-related deaths.
We decided against pooling these data.
Quality of life
Quality of life, measured by the European Organization for Re-
search and Treatment Care Quality of Life Questionnaire, was as-
sessed in the study by Osoba 2002, which used data previously
published in Slamon 2001. The authors showed that higher pro-
portions of patients treated with a combination of trastuzumab
and chemotherapy achieved improvement in global quality of life
than did patients treated by chemotherapy alone.
Blackwell 2010 reported results on quality of life, assessed us-
ing the Functional Assessment of Cancer Therapy-Breast (FACT-
B) questionnaire (version 4). It was reported that changes from
baseline in the combination arm were comparable to the changes
from baseline in the monotherapy arm for all of the subscales,
so none of the differences between the two treatment arms were
statistically significant, but data were not shown. Quality of life
was also assessed in the study by Wu 2011, which used data from
the Blackwell study, using the Functional Assessment of Cancer
Therapy-Breast (FACT-B) questionnaire (version 4). The analyses
presented showed that comparable quality of life was maintained
in both arms during the investigational treatment period.
We decided against pooling these data.
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Sensitivity analysis: trastuzumab efficacy according to
allocation concealment
We judged allocation concealment to be adequate only for
Gasparini 2006, which did not report data on overall survival.
Thus, it was not possible to conduct a sensitivity analysis by al-
location concealment for overall survival with unclear/inadequate
allocation concealment. The HR for progression-free survival in
Gasparini 2006 was 0.70 (95% CI 0.42 to 1.16, P = 0.17); the
HR in the unclear/inadequate subgroup, which represents 94.1%
of the total weight in the meta-analysis, was 0.61 (95% CI 0.53
to 0.70, P < 0.00001; Analysis 4.1). There was no statistically sig-
nificant difference between the two subgroups.
D I S C U S S I O N
Summary of main results
This systematic review allowed us to measure the benefits of
trastuzumab-based therapy in terms of response, progression-free
survival and overall survival, and to quantify the risk of cardiac tox-
icities. The majority of studies were of fairly long duration, with
the median duration of follow-up being two years, and were of
moderate quality, the main weaknesses being the lack of blinding
for progression-free survival and toxicity, and the potential out-
come reporting bias for overall survival in two studies. The results
should therefore be considered with this background in mind.
All studies reported that trastuzumab extends time to disease pro-
gression, with gains varying between two and 11 months, and in
five studies it extended time to death by between five and eight
months. The meta-analysis showed a significant improvement in
overall survival and progression-free survival for trastuzumab-con-
taining regimens, which is possibly greater when considering pa-
tients treated as first-line compared to its use beyond progression,
or patients receiving taxane-based regimens. For severe cardiac tox-
icities, we combined data across studies according to the premise
that the adverse event profile of trastuzumab would be similar ir-
respective of the specific toxicity definition. We found that com-
pared with control treatments, trastuzumab was associated with
statistically significantly higher rates of serious cardiac toxicity.
Subgroup comparisons revealed that the regimens did not differ
from each other with respect to the relative risk of serious cardiac
toxicities. The overall result of the meta-analysis on cardiotoxicity
is influenced by the study of Slamon 2001, which is the first one
that evaluated trastuzumab in addition to an anthracycline-con-
taining regimen. Cardiotoxicity was unexpected at that time. The
other studies do not show the same levels of cardiotoxicity, mainly
due to the adoption of stricter enrolment criteria with respect to
the baseline cardiovascular risk of patients. Indeed, in the subse-
quent trastuzumab studies, a normal baseline cardiac function was
mandatory for study entry.
Human epidermal growth factor receptor 2 (HER2) positivity
is associated with poor prognosis. Trastuzumab represents the
paradigm of successfully developed targeted agents. Indeed, the
target is measurable, the presence of the target is associated with
a poorer outcome and target inhibition led to increased activ-
ity of standard therapy (Gschwind 2004). Moreover, trastuzumab
has shown synergistic interaction with several cytotoxic agents
(Pegram 2004), and its overall tolerability facilitated the com-
bination of trastuzumab with the majority of agents registered
for metastatic breast cancer, with the exception of anthracyclines.
Trastuzumab used in combination therapies produced gains in
absolute survival over older single agents and the magnitude of
these gains was around 7%, as showed in our sensitivity analysis
excluding the study by Blackwell. Strong survival benefits are also
obtained in early breast cancer (Moja 2012). Other molecular tar-
geted therapies, such as bevacizumab or lapatinib, did not pro-
duced similar gains (Mauri 2008; Ioannidis 2010; Gelmon 2012;
Wagner 2012). For instance, in 2008 the FDA granted the accel-
erated approval of bevacizumab plus paclitaxel for advanced breast
cancer (Miller 2007), on the basis of a supposed progression-free
survival benefit. However, in 2010 the FDA removed the indica-
tion due to the lack of overall survival benefit in light of the possi-
ble side effects. A recent interim analysis of a trial designed to com-
pare lapatinib or trastuzumab in combination with taxane-based
chemotherapy for patients with metastatic breast cancer revealed
that patients receiving trastuzumab had a statistically significant
increase in progression-free survival (Gelmon 2012). As a matter
of fact, trastuzumab remains a key, milestone drug in routine clin-
ical practice and should be preferred over other treatment choices.
The possibility of developing cardiac toxicity (left ventricular ejec-
tion fraction (LVEF) decline or congestive heart failure) is a well
known side effect of trastuzumab-based regimens (Moja 2012),
and should be balanced against the benefits. In advanced disease,
however, where the majority of the patients will eventually die
with progressive disease, patients and doctors are likely to accept
a higher risk of toxicity even for a slight survival benefit (Simes
2001). The absence of a statistically significant difference in the
risk of developing severe cardiac toxicity reported in our subgroup
analyses for the combination of trastuzumab with taxanes, aro-
matase inhibitors, capecitabine and lapatinib should not be in-
terpreted as evidence of lack of cardiac toxicities, particularly if
compared with the significant increase when trastuzumab is com-
bined with anthracyclines. The increased risk of developing sig-
nificant cardiotoxicity means that the concomitant administration
of anthracyclines and trastuzumab is not recommended in clin-
ical practice. Indeed, more recently, relatively small neoadjuvant
studies conducted in selected patients with an earlier disease stage
were reassuring in terms of the cardiac safety of combining anthra-
cycline-based regimens and trastuzumab (Guarneri 2012; Buzdar
2013; Schneeweiss 2013). However, the overall limited number of
patients does not allow recommendation of the use of this com-
bination outside a clinical trial. Moreover, in the Z1041 phase III
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randomised study, the concurrent administration of trastuzumab
with anthracyclines resulted in no additional benefit as compared
to the standard administration of anthracyclines followed by tax-
anes-trastuzumab (Buzdar 2013). Currently, the results from this
review inform us about an overall increase of the risk ratio of
congestive heart failure of 3.49 in patients receiving trastuzumab-
based therapy in metastatic breast cancer, irrespective of type of
regimen used in combinationwith trastuzumab. Excluding the an-
thracycline-containing regimens, the RR lowers to 2.06 and fails
to reach statistical significance. This toxicity might be mainly re-
versible and overall has little clinical relevance in the setting of
advanced disease. On the other hand, in a large cohort of patients
with breast cancer treated with trastuzumab outside clinical tri-
als, cardiotoxicity varied considerably across subgroups of patients
(e.g. age and history of cardiac disease were strong predictors of
cardiotoxicity) and the long-term safety profile was less favourable
(Bonifazi 2013).
Trastuzumab does not increase the risk of haematologic toxicities,
such as neutropenic fever and anaemia; it seems to raise the risk
of neutropenia.
Central nervous system (CNS) metastases are another important
issue in HER2-positive disease. Breast cancer is the second most
common cancer that can metastasise to the CNS (Tabouret 2012).
Early studies reported an increased incidence of brainmetastases in
patients receiving trastuzumab. Historically, CNS progression has
occurred late in the clinical course of the disease and survival has
been mainly affected by the lack of systemic disease control. More
recently, the availability of several lines of therapy, alongwith a bet-
ter knowledge of the disease biology, has resulted in a substantial
change in the natural history of the disease. Today, it is well known
that breast cancer is a heterogeneous disease, with a distinct clinical
behaviour and pattern of relapse (Kennecke 2010). The improve-
ment in systemic control is increasing the prevalence of metastatic
breast cancer patients who develop CNS recurrence while having
good extra-CNS disease control. Only one study reported data on
CNS progression, precluding the possibility of drawing definitive
conclusions on this issue. This study showed an almost doubled in-
cidence of CNS progression in trastuzumab-treated patients. The
observed increase of brain metastases in trastuzumab-treated pa-
tients is reasonably a consequence of improved extra-CNS disease
control along with low or no effect on CNS anatomical site.
Few data were found on treatment-related deaths or on quality of
life, making it difficult to understand the impact of trastuzumab
on these.
Overall completeness and applicability of
evidence
The results of ourmeta-analysis cannot be generalised to all women
with metastatic breast cancer in clinical practice. Most of the
women in the studies included in our review were younger than
women usually affected by the disease (median age ranging from
51 to 59 years). Furthermore, the present analysis combines the
results from the registrative RCT, which included women with dif-
ferent baseline risks for cardiotoxicity, and the results from more
recent RCTs, which instead included only women with a normal
baseline risk. The overall results for congestive heart failure are
influenced by the anthracycline-containing regimens of the regis-
trative study, which would not be regarded as standard of care if
in combination with trastuzumab, but the lack of generalisability
of the other included studies may have an impact on the estimates
and the risks may be slightly increased in real-practice settings
(Bonifazi 2013). Therefore, careful cardiac monitoring is required
before and while on trastuzumab-based therapy.
Quality of the evidence
Two trials were closed prematurely because of slow recruitment
and another trial was stopped early for apparent benefit. Three
trials allowed patients in the control arm experiencing progres-
sion to cross over to the trastuzumab arm and in one trial, upon
documented disease progression, two-thirds of the patients were
entered into an extension non-randomised study, in which they
could receive either trastuzumab alone or in combination with
chemotherapy of choice. This can have an impact on the estimates,
since one arm has a continuous exposure to the biologic, whereas
in the other arm the exposure is first to the control treatment and
then the biologic. The consequences of the cross-over lead to prob-
lems in data analysis and the interpretation of results (D’Amico
2011), especially for overall survival in a metastatic setting, so the
risk-benefit profile of trastuzumab might have been modified by
the switch.
Potential biases in the review process
This systematic review has several strengths. We asked a specific
clinical question and the search strategy was comprehensive. We
included any publication of all relevant trials irrespective of lan-
guage.We investigated the potential interaction between the treat-
ment effect and potential effect modifiers. Finally, we rigorously
applied the GRADE criteria for each of the relevant outcomes
(Guyatt 2008).
This review also has limitations. Some readers may question the
pooling of different cardiac toxicities. Since the overall numbers
are relatively small, even limited changes in the definition of severe
congestive heart failure or in LVEF thresholds might be associated
with a higher or lower RR for adverse events.
A limitation of the current subgroup analyses is that they are based
on published group data, rather than individual patient informa-
tion. Individual patient data might allow amore detailed appraisal
of outcomes for each regimen and for patients with different base-
line risks. Still, the power to detect effect modification might still
be limited even with individual patient information, particularly
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for cardiac toxicities. Thus, strong inferences about the specific
efficacy or safety superiority of one particular regimen over the
others should be avoided.
For this review, we limited inclusion to RCTs and their open-la-
bel extensions. Long-term observational studies, including popu-
lation-based registries, can provide realistic estimates of the risks
of trastuzumab in real settings. We are completing the analyses of
a second phase of this project, which will include observational
studies, to address the issue of the frequency of cardiac events out-
side clinical trials, their cumulative incidence over a longer period
and the potential for reversibility.
Agreements and disagreements with other
studies or reviews
We found four other systematic reviews evaluating trastuzumab
for the treatment of HER2-positive metastatic breast cancer
(Mannocci 2010; Fleeman 2011; Harris 2011; Liao 2011). Al-
though the outcomes and the methods do not totally overlap,
there are no major disagreements with the results and conclusions
of our systematic review. Mannocci 2010 considered trastuzumab
beyond progression: the review included 12 observational studies
and the only RCT published at that time (von Minckwitz 2009);
safety was not evaluated. Quality assessment was not done. From
analyses of the observational studies, the authors found no sig-
nificant differences among subgroups defined by type of regimen
(capecitabine or vinorelbine). Fleeman 2011 considered lapatinib
or trastuzumab in combination with an aromatase inhibitor as
first-line treatment. This health technology report included three
RCTs, one assessing the efficacy and safety of lapatinib, and two
assessing the efficacy and safety of trastuzumab (Kaufman 2009,
and a 2009 conference abstract of the trial by Huober 2012). The
authors decided against pooling the data. Harris 2011 evaluated
only the efficacy of HER2-targeted agents. The meta-analysis in-
cluded eight trials, three of them assessing lapatinib and five as-
sessing trastuzumab (Slamon 2001; Marty 2005; Gasparini 2006;
Kaufman 2009; von Minckwitz 2009). There were no subgroup
analyses by type of drug. The results for efficacy were similar to the
results of our systematic review in terms of overall survival (hazard
ratio (HR) 0.78, 95% confidence interval (CI) 0.67 to 0.91), pro-
gression-free survival (HR 0.63, 95% CI 0.53 to 0.74) and overall
response rate (RR 1.67, 95%CI 1.46 to 1.90). Liao 2011 reported
the results in a letter to the editor. Themeta-analysis included four
trials, mixing metastatic and early breast cancer patients. Results
on overall survival, overall response rate and cardiac toxicity did
not differ from our results. None of the other reviews reported
results in absolute terms.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The included trials had limitations: recruitment in three out of
seven studies was slow or stopped early, in three trials more than
50% of patients in the control groups were permitted to switch to
the trastuzumab arms at progression, all studies were open-label
and there is potential selective outcome reporting bias with regard
to overall survival in two studies. There is therefore moderate-
quality evidence that the use of trastuzumab for metastatic breast
cancer: a) improves both overall survival and progression-free sur-
vival in HER2-positive women; and b) increases by between three
and four times the risk of severe cardiac toxicities.
From seven trials involving nearly 1500 women with HER2-pos-
itive metastatic breast cancer, the overall finding was that overall
mortality was reduced by one-fifth after an average of two years of
follow-up, but the risk of heart toxicity was more than three times
greater for women in the group receiving trastuzumab compared
to those receiving standard therapy alone. In absolute terms, if
1000 women were given standard therapy without trastuzumab
then about 300 would survive for at least two years, but if 1000
womenwere treatedwith standard chemotherapy and trastuzumab
until or beyond progression, about 373 would be alive two years
after their diagnosis. However, about 35 in every 1000 women
taking trastuzumab would experience severe heart toxicity, which
is 25 more than for 1000 women taking the standard therapy
alone. These heart problems are often reversible if the treatment
is stopped straight away and, in the context of advanced disease,
patients might choose to accept this risk given the potential ben-
efit.
Treatment beyondprogressionmight involve a greater risk of severe
heart toxicities than first-line treatment, although these results are
based on only two studies and few events.
The review did not identify a trastuzumab-containing regimen
that may have been more or less effective or toxic, with the excep-
tion of the combination with anthracyclines that raises the risk of
severe cardiac toxicity.
The evidence to support the use of trastuzumab beyond progres-
sion in metastatic disease is limited.
Implications for research
Trastuzumab is widely used for women with early breast cancer.
However, despite adjuvant trastuzumab, between 61 and 340 pa-
tients so treated are predicted to relapse and be considered for fur-
ther anti-HER2 directed therapy in the metastatic setting in the
first three years (Moja 2012). The effectiveness of trastuzumab for
these patients is still an open issue since patients enrolled in trials
in the metastatic setting were naive to trastuzumab. It is likely that
the majority of the patients relapsing after adjuvant trastuzumab
will be offered trastuzumab again even if the evidence of benefit is
indirect. In ourGRADE analysis we did not downgrade the overall
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quality of the evidence for the primary endpoints for indirectness.
Guideline panellists need to explore carefully the implications of
this issue.
In women with metastatic cancer progressing while on
trastuzumab it is important to test either the continuation or stop-
ping of trastuzumab or to switch to other options: lapatinib, per-
tuzumab and TDM-1. The optimal therapeutic strategy for this
growing group of patients is still a matter of debate.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Blackwell 2010
Methods Accrual time: November 2005 to November 2006
Multi-centre, international
Baseline comparability: balanced
Participants 296 female enrolled
Age: trastuzumab arm: median 52, range from 26 to 81; control arm: median 51, range
from 29 to 78
Diagnosis: metastatic breast cancer progressed during prior trastuzumab-based therapy
Inclusion criteria: women ≥ 18 years of age with histologically or cytologically con-
firmed BC. Patients must have metastatic disease that progressed on their most recent
treatment regimen, which must have contained trastuzumab. Tumours with ErbB2 gene
amplification as measured by fluorescence in situ hybridisation or ErbB2 over-expression
as measured by immunohistochemistry (3+). Patients must have received prior anthra-
cycline- and taxane-based regimens in either the adjuvant or metastatic setting. Eligible
patients had at least 1 measurable lesion according to Response Evaluation Criteria in
Solid Tumors (RECIST) or bone-only disease. ECOG performance status of ≤ 2; ade-
quate haematologic, renal and hepatic function; and a cardiac ejection fraction within
the institutional normal range. Written informed consent
Exclusion criteria: see inclusion criteria
HER2+: 100%
Interventions 2-arm RCT
Trastuzumab arm (randomised N = 148): oral lapatinib (1000 mg daily) in combination
with intravenous trastuzumab (2 mg/kg weekly, after the initial 4 mg/kg loading dose)
Control arm (randomised N = 148): oral lapatinib (1500 mg daily)
Outcomes Primary: progression-free survival
Secondary: ORR (confirmed complete response plus partial response), clinical benefit
response rate (confirmed complete response plus partial response at any time, plus stable
disease for ≥ 24 weeks), OS, quality of life, safety
Notes Study ID: EGF104900
Median length of time on study: 12.8 months (range 0.4 to 31.3) for patients receiving
lapatinib + trastuzumab; 8.7 months (range 0.8 to 29.2) for patients receiving lapatinib
alone
1 patient randomly assigned to the combination group did not receive study treatment,
and 2 patients randomly assigned to lapatinib monotherapy received lapatinib in com-
bination with trastuzumab, accounting for small differences between the ITT and safety
populations
Patients analysed for ORR: trastuzumab arm N = 146; control arm N = 145
Patients analysed for safety: trastuzumab arm N = 149; control arm N = 146
Patients with objective disease progression after receiving at least 4 weeks of study treat-
ment with lapatinib monotherapy were permitted to cross over to combination therapy:
77 patients (52%) crossed over after progression
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Blackwell 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Overall Survival
High risk Open-label
Blinding of outcome assessment (detection
bias) (OS)
Low risk Open-label, but our primary outcome (i.e.
OS) is not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias) (outcomes other than OS)
Unclear risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although 26 patients (9%) had withdrawn
consent or were lost to follow-up before
death, only 8 patients (2.7%) were lost to
follow-up before progression (PFS is the
primary outcome of the study)
Selective reporting (reporting bias) Low risk The protocol for the study is available (
http://www.clinicaltrials.gov/ct2/show/
NCT00320385). All of the study pre-spec-
ified primary outcomes that are of interest
in the review have been reported
Gasparini 2006
Methods Accrual time: December 2000 to September 2004
Multi-centre, national (Italy)
Baseline comparability: balanced
Participants 123 female enrolled
Age: trastuzumab arm: median 56, range from 32 to 72; control arm:median 54.3, range
from 30 to 71
Diagnosis: untreated metastatic breast cancer
Inclusion criteria: women over-expressing HER2/neu by the Hercep Test assay (score
2+ or 3+), measurable disease, age ≥ 18 years, performance status ≤ 2 according to
the ECOG scale, life expectancy > 3 months and adequate organ function, defined as
follows: LVEF > 50% or within normal limits, AST and ALT levels ≤ 2.5 times the
normal value, total bilirubin < 1.5 the normal value, serum creatinine levels≤ 1.5 mg/dl,
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Gasparini 2006 (Continued)
neutrophils ≥ 2000/mm3, platelets ≥ 100.000 mm3, haemoglobin > 10 g/dl. Patients
may have received an anthracycline and/or taxane-containing regimen given as adjuvant
chemotherapy and relapsed > 12 months following the end of chemotherapy
Exclusion criteria: patients were excluded if they had received previous chemotherapy for
metastatic disease, brain, leptomeningeal or bone metastases as the only site of disease,
a positive history for other types of cancer, with the exception of in situ cervix cancer
radically resected and non melanoma skin cancer, prior history of myocardial infarction,
unstable angina pectoris, cardiac insufficiency, uncontrolled arrhythmia or hypertension,
peripheral neuropathy of grade ≥ 2 or pregnancy
HER2+: 100%
Interventions 2-arm RCT
Trastuzumab arm (randomised N = 63): paclitaxel (80 mg/m2 weekly) plus trastuzumab
(first loading dose of 4 mg/kg, followed by weekly doses of 2 mg/kg until disease pro-
gression)
Control arm (randomisedN=60): paclitaxel (80mg/m2 weekly until disease progression)
Outcomes Primary: ORR
Secondary: safety profile, TTP and duration of response
Notes Median follow-up for efficacy: 16.6 for both arms
Trial stopped early for benefit. Interim analyses not planned in the RCT protocol
Stopping characteristics:
- Interim analyses: after the first 124 patients enrolled (sample size planned not reported)
- Outcome: ORR
- Details of stop: trialists interrupted the accrual but monitored follow-up of enrolled
patients
- Monitoring methods/stopping boundaries: not planned - the decision was based on: 1.
data fromother trials suggesting that only the patients with strongHER2 over-expression
(3+) gain benefit from trastuzumab; 2. trial results confirmed a statistically significant
superior outcome for the patients HER2-3+; 3. the planned statistical difference of 15%
for ORR was reached
- Role of monitoring committee: not described
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1 randomisation stratified according to
visceral involvement, HER2/neu over-ex-
pression and centre
Allocation concealment (selection bias) Low risk The patients were allocated by the indepen-
dentmonitoring agency to treatment group
by randomisation code envelopes
Blinding of participants and personnel
(performance bias)
Overall Survival
High risk Open-label
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Gasparini 2006 (Continued)
Blinding of outcome assessment (detection
bias) (OS)
Low risk Open-label, but our primary outcome (i.e.
OS) is not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias) (outcomes other than OS)
Unclear risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk 124 patients enrolled: 123 patients assess-
able for efficacy and safety and 118 for
ORR
Selective reporting (reporting bias) High risk Protocol not found
Results for OS not shown
Huober 2012
Methods Accrual time: 2003 to 2007
Multi-centre, international
Baseline comparability: more patients in the control arm (71%) than in the trastuzumab
arm (42%) had received adjuvant systemic treatment. Tamoxifen was exclusively used
for adjuvant endocrine treatment (given in 65% and 31% of patients, respectively)
Participants 57 female enrolled
Age: trastuzumab arm: median 61.5, range from 39 to 87; control arm: median 61, range
from 47 to 88
Diagnosis: HER2 and hormone receptor-positive metastatic breast cancer or locally
advanced breast cancer
Inclusion criteria: postmenopausal women with newly diagnosed hormone receptor-
positive MBC or LABC defined as ER and/or PgR ≥ 10 fmol/mg cytosol protein, or
≥ 10% of the tumour cells positive as assessed by immunohistochemical evaluation of
the primary tumour. For the trastuzumab and control arms, the primary tumour had
to reveal HER2 over-expression defined as 3+ staining by IHC or HER2 amplification
(ratio > 2) by FISH or an equivalent method. No prior treatment for metastatic or locally
advanced breast cancer; LVEF ≥ 50% at baseline; adequate hepatic, renal and bone
marrow function; an ECOG performance status of 0 or 1. Furthermore, patients were
required to have at least 1 measurable tumour lesion (patients with bone only disease
were eligible)
Exclusion criteria: clinical or radiological signs of CNS metastasis; inflammatory breast
cancer; other concurrent or previous malignant disease; uncontrolled cardiac diseases;
prior anti-HER2 therapy apart from trastuzumab in the adjuvant setting
HER2+: 61.3% (57/93). We considered HER2+ women alone
Interventions 2-arm RCT
Trastuzumab arm (randomised N = 26): letrozole (2.5 mg once daily) plus trastuzumab
(first loading dose of 4 mg/kg, followed by weekly doses of 2 mg/kg until disease pro-
gression) iv until progression of disease. As of May 2005 trastuzumab was allowed to be
given as 3-weekly application with the typical dose of 6 mg/kg (after a loading dose of
8 mg/kg)
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Huober 2012 (Continued)
Control arm (randomised N = 31): letrozole (2.5mg once daily until disease progression)
In addition, in an amendment for German sites, a third arm (N = 35) was implemented
where patients with HER2-negative and hormone receptor-positive tumours were as-
signed to receive letrozole alone as first-line treatment
Outcomes Primary: time to disease progression (interval between the date of randomisation/start of
treatment and the earliest date of progression, or of death due to the underlying breast
cancer, or of death from a cause thought to be connected to the underlying disease)
Secondary: TTF, ORR/CBR, duration of response/clinical benefit and OS
Notes Study ID: eLEcTRA
Median follow-up: not specified
Closed prematurely due to slow recruitment: the total number of patients to be recruited
in the trastuzumab and the control arms was planned to be 300 (150 per arm)
Trastuzumabwas admitted as second-line treatment in 31%and the 52%of the treatment
and control arms respectively
ClinicalTrials identifier: NCT00171847
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Overall Survival
High risk Open-label
Blinding of outcome assessment (detection
bias) (OS)
Low risk Open-label, but our primary outcome (i.e.
OS) is not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias) (outcomes other than OS)
Unclear risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk The protocol for the study
is available (http://www.clinicaltrials.gov/
ct2/show/NCT00171847).
Results on OS not shown
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Kaufman 2009
Methods Accrual time: 2001 to 2004
Multi-centre, international
Baseline comparability: balanced
Co-intervention: in the trastuzumab plus anastrozole arm, patients had almost twice the
duration of exposure to anastrozole compared with patients receiving anastrozole alone
(median, 189 days compared to 98 days, respectively)
Participants 208 female enrolled
Age: trastuzumab arm: median 56, range from 31 to 85; control arm: median 54, range
from 27 to 77
Diagnosis: metastatic breast cancer
Inclusion criteria: postmenopausal women over-expressing HER2/neu by the Hercep
Test assay (score 2+or 3+), and/or fluorescence in situ hybridisationpositivewith two-fold
amplification, hormone receptor-positive (ER-positive and/or PgR-positive). Previous
treatment with tamoxifen as adjuvant or hormonal therapy or anastrozole was permitted.
Other requirements included a LVEF greater than 50%; adequate baseline hepatic, renal
and bone marrow function; an ECOG performance status of 0 to 1; and measurable or
evaluable disease
Exclusion criteria: prior chemotherapy for MBC or adjuvant chemotherapy within 6
months, clinical or radiologic evidence of CNS metastases; history of another malig-
nancy, CHF or uncontrolled cardiac disease (angina, arrhythmias, hypertension); un-
controlled serious intercurrent illness; and severe dyspnoea at rest. Patients with previous
radiotherapy to indicator lesions were excluded from the response evaluation
HER2+: not reported
Interventions 2-arm RCT
Trastuzumab arm (randomised N = 104): anastrozole (1 mg/d orally) plus trastuzumab
(first loading dose of 4 mg/kg, followed by weekly doses of 2 mg/kg) until disease
progression
Control arm (randomised N = 104): anastrozole (1mg/d orally) until disease progression
Outcomes Primary: progression-free survival
Secondary: clinical benefit rate, overall response rate, time to disease progression, time
to treatment failure, duration of response
Notes Median follow-up for efficacy: not reported
Upon documented disease progression, 58 of 103 patients (56.3%) crossed over from
anastrozole alone to trastuzumab while 15 patients (14.6%) received trastuzumab after
study withdrawal
Response data were reported for only 147 patients (70.6%; trastuzumab plus anastrozole,
n = 74; anastrozole alone, n = 73).
Hormone receptor positivity was confirmed in the central laboratory for 150 patients
(trastuzumab plus anastrozole, n = 77; anastrozole alone, n = 73). ER/PgR negativity
was found centrally in 44 patients (trastuzumab plus anastrozole, n = 21; anastrozole
alone, n = 23) and central confirmation was not possible in 13 patients (trastuzumab
plus anastrozole, n = 5; anastrozole alone, n = 8)
Risk of bias
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Kaufman 2009 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment was conducted using
a minimisation procedure, with stratifica-
tion according to presence of liver metas-
tases; measurable versus evaluable disease;
time to relapse after adjuvant tamoxifen, if
administered; and bisphosphonate therapy
at enrolment
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Overall Survival
High risk Open-label
Blinding of outcome assessment (detection
bias) (OS)
Low risk Open-label, but our primary outcome (i.e.
OS) is not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias) (outcomes other than OS)
Low risk Open-label, but it is stated that “A recon-
ciled data set, which integrated the tumor
response/date of progression as determined
by the investigator and a blinded Response
Evaluation Committee, was used for the
primary analyses. An independent oncolo-
gist reconciled cases where investigator and
committee assessments differed.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 208 patients
enrolled: 1 patient (trastuzumab plus anas-
trozole arm) withdrew before receiving the
first dose. 207 patients assessable for effi-
cacy and toxicity (although response data
were reported for only 147 patients (70.
6%))
Selective reporting (reporting bias) Unclear risk Protocol not found
Results for primary and secondary out-
comes are reported in published papers: it
is likely that reporting bias has not occurred
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Marty 2005
Methods Accrual time: April 2000 to October 2002
Multi-centre, international
Baseline comparability: baseline patients characteristics were generally balanced between
the 2 arms, although there were more patients with oestrogen receptor- or progesterone
receptor-positive disease in the docetaxel alone arm compared with the combination arm
(56% versus 41%) and more patients had received prior (neo)adjuvant anthracyclines in
the combination arm (64% versus 55%)
Participants 188 female enrolled
Age: trastuzumab arm: median 53, range from 32 to 80; control arm: median 55; range
from 24 to 79
Diagnosis: metastatic breast cancer
Inclusion criteria: women age 18 to 70 years with HER2 over-expression (IHC 3+) and/
or gene amplification (FISH positive) who had not previously received chemotherapy for
metastatic disease. Patients could have received prior (neo)adjuvant anthracyclines (max-
imum cumulative dose, 360 mg/m2 doxorubicin or 750 mg/m2 epirubicin). Baseline
LVEF had to be more than 50%. Hormonal therapy had to be discontinued before the
first dose of study drug. Previous radiotherapy was allowed only if treatment had ended
at least 14 days before enrolment into the trial and the patient had fully recovered from
all acute adverse effects. ECOG performance status of ≤ 2, life expectancy ≥ 12 weeks,
and at least one bidimensionally measurable lesion (according to WHO criteria). Bone
marrow, renal and hepatic function: haemoglobin ≥ 10 g/dL and no blood transfusion
within the previous 2 weeks; neutrophil count ≥ 2.0 x 109 cells/L; platelet count ≥
100 x 109 cells/L; no evidence of myelodysplastic syndrome or abnormal bone marrow
reserve; creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine clearance ≥ 60
mL/min; total bilirubin less than 1 x ULN; AST and/or ALT≤ 2.5 x ULN; and alkaline
phosphatase ≤ 5 x ULN (patients with AST and/or ALT > 1.5 x ULN concomitantly
with alkaline phosphatase > 2.5 x ULN were ineligible for the study)
Exclusion criteria: patients who had received prior chemotherapy for their metastatic
disease or any prior taxanes or anti-HER therapywere excluded. Patientswhohadbrain or
leptomeningealmetastases, significant cardiac insufficiency (NewYorkHeart Association
III or IV), myocardial infarction within the previous 6 months, unstable angina pectoris,
uncontrolled arrhythmia, or advancedpulmonary disease or severe dyspnoea at rest due to
complications of advanced malignancy, or who required supplementary oxygen therapy,
were ineligible for the trial
HER2+: group 1: 97%; group 2: 94%
Interventions 2-arm RCT
Trastuzumab arm (randomised N = 94): docetaxel (100 mg/m2 every 21 days for 6
cycles) plus trastuzumab (first loading dose of 4 mg/kg, followed by weekly doses of 2
mg/kg until disease progression)
Control arm (randomised N = 94): docetaxel (100 mg/m2 every 21 days for 6 cycles)
Outcomes Primary: ORR
Secondary: OS, duration of response, time to disease progression, time to treatment
failure
Notes Study ID: M77001 Study Group
Median follow-up for efficacy: 24 months; minimum, maximum not reported
Upon documented disease progression, 53 of 94 patients (57%) crossed over from doc-
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Marty 2005 (Continued)
etaxel alone to trastuzumab
Patients analysed: trastuzumab arm N = 92; control arm N = 94
Patients analysed for cardiac safety: trastuzumab arm N = 86; control arm N = 76
OS: HR estimated using the ratio of the medians. HR variance estimated using number
of deaths in the 2 groups. Time to progression: HR estimated using the ratio of the
medians. HR variance estimated using the relationship between Chi2 and the log of the
HR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random assignment to treatment, block by
country
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Overall Survival
High risk Open-label
Blinding of outcome assessment (detection
bias) (OS)
Low risk Open-label, but our primary outcome (i.e.
OS) is not likely to be influenced by lack
of blinding
Blinding of outcome assessment (detection
bias) (outcomes other than OS)
Unclear risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 patients (both in the trastuzumab plus
docetaxel arm) withdrew before receiving
the first dose. 7 patients in the docetaxel
alone arm withdrew at cycle 1 or 2
Selective reporting (reporting bias) Low risk The protocol for the study
is available (http://www.roche-trials.com/
studyResultGet.action?
studyResultNumber=M77001)
Slamon 2001
Methods Accrual time: June 1995 to March 1997
Multi-centre, international
Baseline comparability: balanced
Participants 469 female enrolled
Age: trastuzumab + anthracycline arm: mean 54, range from 27 to 76; anthracycline
control arm: mean 54, range from 25 to 75; trastuzumab + taxane arm: mean 51, range
from 25 to 77; taxane control arm: mean 51, range from 26 to 73
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Slamon 2001 (Continued)
Diagnosis: progressive metastatic breast cancer
Inclusion criteria: women over-expressing HER2 who had not previously received che-
motherapy for metastatic disease. Only patients who had weak-to-moderate staining of
the entire tumour cell membrane for HER2 (referred to as a score of 2+) or more than
moderate staining (referred to as a score of 3+) in more than 10% of tumour cells on
immunohistochemical analysis were eligible
Exclusion criteria: patients were excluded if they had bilateral breast cancer, untreated
brain metastases, osteoblastic bone metastases, pleural effusion or ascites as the only
evidence of disease, a second type of primary cancer, or a Karnofsky score of less than 60,
if they were pregnant or had received any type of investigational agent within 30 days
before the study began
HER2+: 100%
Interventions 4-arm RCT
Trastuzumab + anthracycline arm (randomised N = 143): doxorubicin (or epirubicin)
plus cyclophosphamide (60 mg/m2 (75 mg/m2) and 600 mg/m2 every 21 days for 6
cycles) plus trastuzumab (first loading dose of 4 mg/kg, followed by weekly doses of 2
mg/kg until disease progression)
Anthracycline control arm (randomised N = 138): doxorubicin (or epirubicin) plus
cyclophosphamide (60 mg/m2 (75 mg/m2) and 600 mg/m2 every 21 days for 6 cycles)
Trastuzumab + taxane arm (randomised N = 92): paclitaxel (175 mg/m2 every 21 days
for 6 cycles) plus trastuzumab (first loading dose of 4 mg/kg, followed by weekly doses
of 2 mg/kg until disease progression)
Taxane control arm (randomised N = 96): paclitaxel (175 mg/m2 every 21 days for 6
cycles)
Trastuzumab + anthracycline and anthracycline control arms: 100% patients naive to
previous anthracycline chemotherapy
Trastuzumab + taxane and taxane control arm: 97% patients previously treated with
adjuvant anthracycline chemotherapy
Outcomes Primary: time to disease progression (disease progression was defined as an increase of
more than 25% in the dimensions of any measurable lesion)
Secondary: OS, ORR, the duration of a response, the time to treatment failure (a com-
posite of disease progression, death, discontinuation of treatment and the use of other
types of antitumour therapy)
Notes Study ID: HO648g
Median follow-up for efficacy: 30 months (30 min to 51 max)
Upon documented disease progression patients (66%) were entered into the extension
study H0659g, a non-randomised, open-label study in which they could receive either
trastuzumab alone or in combination with chemotherapy of choice
We found possible inconsistencies among different data reports (FDA Statistical Review
- Trastuzumab Product Approval Information - Licensing Action 9/25/98, EMEA EPAR
H-C-278 Scientific discussion for the approval of Herceptin 2004). For this systematic
review we considered the NEJM publication as our primary data source
OS: HR estimated using the ratio of the medians. HR variance estimated using the
relationship between Chi2 and the log of the HR. Time to progression: HR estimated
using the ratio of the medians. HR variance estimated using the relationship between
Chi2 and the log of the HR
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Slamon 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Stratification on the basis of history of ad-
juvant anthracycline treatment
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Overall Survival
High risk Open-label
Blinding of outcome assessment (detection
bias) (OS)
Low risk Open-label (original double-blind design
was abandoned due to ethical considera-
tions), but our primary outcome (i.e.OS) is
not likely to be influenced by lack of blind-
ing
Blinding of outcome assessment (detection
bias) (outcomes other than OS)
Unclear risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Enrolled 469patients. 5 patientswere never
treated; 2 decline treatment; 1 died before
treatment; 1 had disease progression at en-
rolment; 1 was enrolled inadvertently
Selective reporting (reporting bias) Low risk The protocol for the study is avail-
able (http://www.cancer.gov/clinicaltrials/
search/view?cdrid=64329&
version=HealthProfessional&
protocolsearchid=6378103)
von Minckwitz 2009
Methods Accrual time: September 2003 to June 2007
Multi-centre, international
Baseline comparability: 3 to 4 T stage at first diagnosis more frequent in the capecitabine
+ trastuzumab arm than in the capecitabine alone arm (respectively: 34% and 14%)
Participants 156 female enrolled
Age: capecitabine arm: median 59, range from 33 to 82; capecitabine + trastuzumab
arm: median 52.5, range from 28 to 78
Diagnosis: pathologically confirmed, HER2-positive, locally advanced or metastatic
breast cancer
Inclusion criteria: women with pathologically confirmed, HER2-positive, locally ad-
vanced or metastatic breast cancer. HER2 status was considered positive if over-expres-
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von Minckwitz 2009 (Continued)
sion was detected in either the primary or metastatic tumour tissue by local immunohis-
tochemistry (grade 3+ staining intensity) or by fluorescence in situ hybridisation. Du-
ration of previous trastuzumab treatment had to be 12 weeks or greater, and the time
since the end of the last trastuzumab cycle had to be less than 6 weeks. Patients could
have received up to 1 chemotherapy drug for metastatic disease. Karnofsky performance
status of 60% or greater; a life expectancy of greater than 3 months; and adequate hae-
matologic, renal, hepatic and cardiac function sonographically confirmed by a LVEF of
50% or greater. Written informed consent
Exclusion criteria: see inclusion criteria
HER2+: 100%
Interventions 2-arm RCT
Trastuzumab arm (randomised N = 78): capecitabine (2500 mg/m2 (1250 mg/m2 semi-
daily) on days 1 through 14 followed by 1 week of rest) plus trastuzumab (6 mg/kg every
3 weeks until disease progression or unacceptable toxicity)
Control arm (randomised N = 78): capecitabine (2500 mg/m2 (1250 mg/m2 semi-daily)
on days 1 through 14 followed by 1 week of rest)
Outcomes Primary: time to progression (time period between random assignment and documented
disease progression or disease-related death)
Secondary: response of tumour lesions; clinical benefit (complete response, partial re-
sponse or disease stabilisation for greater than 24 weeks); duration of response (time
period between first notification of a response and the date of documented progression,
disease-related death or withdrawal); OS
Notes Study ID: GBG-26
Median follow-up: 20.7 months
As accrual was slowing down, the trial was closed in agreement with the IDMC on 1
July 2007
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment list was prepared be-
fore stratification (by pretreatment and
participating centre); a block permutation
method with a block size of 4 was used
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Overall Survival
High risk Open-label
Blinding of outcome assessment (detection
bias) (OS)
Low risk Open-label, but our primary outcome (i.e.
OS) is not likely to be influenced by lack
of blinding
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von Minckwitz 2009 (Continued)
Blinding of outcome assessment (detection
bias) (outcomes other than OS)
Unclear risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Enrolled 156patients. 5 patientswere never
treated; 151patients received at least 1 cycle
of allocated treatment
Selective reporting (reporting bias) Unclear risk The protocol
is available (http://www.clinicaltrials.gov/
ct2/show/NCT00320385)
In the paper published in 2011, only up-
dated results for OS are reported
ALT: alanine aminotransferase
AST: aspartate aminotransferase
BC: breast cancer
CBR: clinical benefit rate
CHF: congestive heart failure
CNS: central nervous system
ECOG: Eastern Cooperative Oncology Group
ER: oestrogen receptor
FDA: (US) Food and Drug Administration
FISH: fluorescence in situ hybridisation
HER2: human epidermal growth factor receptor 2
HR: hazard ratio
IDMC: Independent Data Monitoring Committee
IHC: immunohistochemistry
ITT: intention-to-treat
iv: intravenous
LABC: locally advanced breast cancer
LVEF: left ventricular ejection fraction
MBC: metastatic breast cancer
NEJM: New England Journal of Medicine
ORR: overall response rate
OS: overall survival
PFS: progression-free survival
PgR: progesterone receptor
RCT: randomised controlled trial
TTF: time to failure
TTP: time to progression
ULN: upper limit of normal
WHO: World Health Organization
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gelmon 2012 Head-to-head comparison of trastuzumab and lapatinib
Papaldo 2006 Not randomised, all HER2-positive patients were given trastuzumab
Raff 2004 Not randomised, all HER2-positive patients were given trastuzumab
HER2: human epidermal growth factor receptor 2
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D A T A A N D A N A L Y S E S
Comparison 1. Efficacy of trastuzumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival - all studies 5 Hazard Ratio (Random, 95% CI) 0.82 [0.71, 0.94]
2 Overall survival - excluding
Blackwell
4 Hazard Ratio (Random, 95% CI) 0.82 [0.70, 0.95]
3 Overall survival - stratified by
type of regimen
4 Hazard Ratio (Random, 95% CI) 0.81 [0.70, 0.93]
3.1 Taxane-containing
regimen
2 Hazard Ratio (Random, 95% CI) 0.80 [0.65, 0.99]
3.2 Anthracycline-containing
regimen
1 Hazard Ratio (Random, 95% CI) 0.80 [0.59, 1.10]
3.3 Aromatase
inhibitor-containing regimen
1 Hazard Ratio (Random, 95% CI) 0.84 [0.59, 1.19]
3.4 Other 1 Hazard Ratio (Random, 95% CI) 0.80 [0.56, 1.14]
4 Overall survival - stratified by
treatment line
5 Hazard Ratio (Random, 95% CI) 0.82 [0.71, 0.94]
4.1 First-line 3 Hazard Ratio (Random, 95% CI) 0.79 [0.67, 0.94]
4.2 Beyond progression 2 Hazard Ratio (Random, 95% CI) 0.87 [0.68, 1.12]
5 Progression-free survival - all
studies
7 Hazard Ratio (Random, 95% CI) 0.61 [0.54, 0.70]
6 Progression-free survival -
excluding Blackwell
6 Hazard Ratio (Random, 95% CI) 0.58 [0.50, 0.66]
7 Progression-free survival -
stratified by type of regimen
7 Hazard Ratio (Random, 95% CI) 0.67 [0.59, 0.77]
7.1 Taxane-containing
regimen
3 Hazard Ratio (Random, 95% CI) 0.53 [0.42, 0.68]
7.2 Anthracycline-containing
regimen
1 Hazard Ratio (Random, 95% CI) 0.78 [0.68, 0.91]
7.3 Aromatase
inhibitor-containing regimen
2 Hazard Ratio (Random, 95% CI) 0.64 [0.49, 0.83]
7.4 Other 2 Hazard Ratio (Random, 95% CI) 0.72 [0.59, 0.88]
8 Progression-free survival -
stratified by treatment line
7 Hazard Ratio (Random, 95% CI) 0.61 [0.54, 0.70]
8.1 First-line 5 Hazard Ratio (Random, 95% CI) 0.56 [0.49, 0.65]
8.2 Beyond progression 2 Hazard Ratio (Random, 95% CI) 0.72 [0.59, 0.88]
9 Overall response rate - all studies 7 1419 Risk Ratio (IV, Random, 95% CI) 1.58 [1.38, 1.82]
10 Overall response rate - stratified
by type of regimen
7 1419 Risk Ratio (IV, Random, 95% CI) 1.61 [1.35, 1.91]
10.1 Taxane-containing
regimen
3 492 Risk Ratio (IV, Random, 95% CI) 1.71 [1.23, 2.38]
10.2Anthracycline-containing
regimen
1 281 Risk Ratio (IV, Random, 95% CI) 1.33 [1.04, 1.70]
10.3 Aromatase
inhibitor-containing regimen
2 204 Risk Ratio (IV, Random, 95% CI) 2.55 [1.23, 5.27]
42Trastuzumab-containing regimens for metastatic breast cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
10.4 Other 2 442 Risk Ratio (IV, Random, 95% CI) 1.70 [1.16, 2.49]
11 Overall response rate - stratified
by treatment line
7 1419 Risk Ratio (IV, Random, 95% CI) 1.58 [1.38, 1.82]
11.1 First-line 5 977 Risk Ratio (IV, Random, 95% CI) 1.57 [1.34, 1.84]
11.2 Beyond progression 2 442 Risk Ratio (IV, Random, 95% CI) 1.70 [1.16, 2.49]
Comparison 2. Cardiac toxicity of trastuzumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Congestive heart failure - all
studies
7 1459 Risk Ratio (IV, Random, 90% CI) 3.49 [1.88, 6.47]
2 Congestive heart failure -
stratified by type of regimen
7 1459 Risk Ratio (IV, Random, 90% CI) 3.37 [1.81, 6.27]
2.1 Taxane-containing
regimen
3 471 Risk Ratio (IV, Random, 90% CI) 1.98 [0.54, 7.26]
2.2 Anthracycline-containing
regimen
1 278 Risk Ratio (IV, Random, 90% CI) 5.43 [2.28, 12.94]
2.3 Aromatase
inhibitor-containing regimen
2 264 Risk Ratio (IV, Random, 90% CI) 1.01 [0.20, 5.15]
2.4 Other 2 446 Risk Ratio (IV, Random, 90% CI) 5.31 [0.87, 32.20]
3 Congestive heart failure -
stratified by treatment line
7 1459 Risk Ratio (IV, Random, 90% CI) 3.49 [1.88, 6.47]
3.1 First-line 5 1013 Risk Ratio (IV, Random, 90% CI) 3.30 [1.71, 6.37]
3.2 Beyond progression 2 446 Risk Ratio (IV, Random, 90% CI) 5.31 [0.87, 32.20]
4 Left ventricular ejection fraction
(LVEF) decline - all studies
5 938 Risk Ratio (IV, Random, 90% CI) 2.65 [1.48, 4.74]
5 LVEF decline - stratified by type
of regimen
5 938 Risk Ratio (IV, Random, 90% CI) 2.65 [1.48, 4.74]
5.1 Taxane-containing
regimen
2 285 Risk Ratio (IV, Random, 90% CI) 2.36 [1.12, 4.96]
5.2 Aromatase
inhibitor-containing regimen
1 207 Risk Ratio (IV, Random, 90% CI) 3.03 [0.21, 44.02]
5.3 Other 2 446 Risk Ratio (IV, Random, 90% CI) 3.21 [1.19, 8.64]
6 LVEF decline - stratified by
treatment line
5 938 Risk Ratio (IV, Random, 90% CI) 2.65 [1.48, 4.74]
6.1 First-line 3 492 Risk Ratio (IV, Random, 90% CI) 2.40 [1.17, 4.91]
6.2 Beyond progression 2 446 Risk Ratio (IV, Random, 90% CI) 3.21 [1.19, 8.64]
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Comparison 3. Other toxicities
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Neutropenic fever - all studies 3 460 Risk Ratio (IV, Random, 90% CI) 1.38 [0.86, 2.21]
2 Neutropenic fever - stratified by
type of regimen
3 460 Risk Ratio (IV, Random, 90% CI) 1.38 [0.86, 2.21]
2.1 Taxane-containing
regimen
2 309 Risk Ratio (IV, Random, 90% CI) 1.32 [0.82, 2.13]
2.2 Other 1 151 Risk Ratio (IV, Random, 90% CI) 4.81 [0.38, 60.61]
3 Neutropenic fever - stratified by
treatment line
3 460 Risk Ratio (IV, Random, 90% CI) 1.38 [0.86, 2.21]
3.1 First-line 2 309 Risk Ratio (IV, Random, 90% CI) 1.32 [0.82, 2.13]
3.2 Beyond progression 1 151 Risk Ratio (IV, Random, 90% CI) 4.81 [0.38, 60.61]
4 Anaemia - all studies 4 924 Risk Ratio (IV, Random, 90% CI) 0.93 [0.37, 2.35]
5 Anaemia - stratified by type of
regimen
4 924 Risk Ratio (IV, Random, 90% CI) 0.92 [0.37, 2.32]
5.1 Taxane-containing
regimen
3 495 Risk Ratio (IV, Random, 90% CI) 1.03 [0.20, 5.30]
5.2 Anthracycline-containing
regimen
1 278 Risk Ratio (IV, Random, 90% CI) 1.26 [0.36, 4.35]
5.3 Other 1 151 Risk Ratio (IV, Random, 90% CI) 0.19 [0.02, 2.42]
6 Anaemia - stratified by treatment
line
4 924 Risk Ratio (IV, Random, 90% CI) 0.93 [0.37, 2.35]
6.1 First-line 3 773 Risk Ratio (IV, Random, 90% CI) 1.19 [0.44, 3.19]
6.2 Beyond progression 1 151 Risk Ratio (IV, Random, 90% CI) 0.19 [0.02, 2.42]
7 Neutropenia - all studies 3 460 Risk Ratio (IV, Random, 90% CI) 1.46 [1.02, 2.08]
8 Neutropenia - stratified by type
of regimen
3 460 Risk Ratio (IV, Random, 90% CI) 1.46 [1.02, 2.08]
8.1 Taxane-containing
regimen
2 309 Risk Ratio (IV, Random, 90% CI) 1.48 [1.02, 2.14]
8.2 Other 1 151 Risk Ratio (IV, Random, 90% CI) 1.28 [0.38, 4.37]
9 Neutropenia - stratified by
treatment line
3 460 Risk Ratio (IV, Random, 90% CI) 1.46 [1.02, 2.08]
9.1 First-line 2 309 Risk Ratio (IV, Random, 90% CI) 1.48 [1.02, 2.14]
9.2 Beyond progression 1 151 Risk Ratio (IV, Random, 90% CI) 1.28 [0.38, 4.37]
Comparison 4. Sensitivity analysis: progression-free survival - by allocation concealment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression-free survival - by
allocation concealment
7 Hazard Ratio (Random, 95% CI) 0.61 [0.54, 0.70]
1.1 Adequate 1 Hazard Ratio (Random, 95% CI) 0.70 [0.42, 1.16]
1.2 Unclear/inadequate 6 Hazard Ratio (Random, 95% CI) 0.61 [0.53, 0.70]
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Analysis 1.1. Comparison 1 Efficacy of trastuzumab, Outcome 1 Overall survival - all studies.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 1 Overall survival - all studies
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Marty 2005 -0.32 (0.19) 13.6 % 0.73 [ 0.50, 1.05 ]
von Minckwitz 2009 -0.06 (0.18) 15.2 % 0.94 [ 0.66, 1.34 ]
Kaufman 2009 -0.18 (0.18) 15.2 % 0.84 [ 0.59, 1.19 ]
Blackwell 2010 -0.22 (0.18) 15.2 % 0.80 [ 0.56, 1.14 ]
Slamon 2001 -0.22 (0.11) 40.7 % 0.80 [ 0.65, 1.00 ]
Total (95% CI) 100.0 % 0.82 [ 0.71, 0.94 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.06, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.90 (P = 0.0038)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Efficacy of trastuzumab, Outcome 2 Overall survival - excluding Blackwell.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 2 Overall survival - excluding Blackwell
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Marty 2005 -0.32 (0.19) 16.1 % 0.73 [ 0.50, 1.05 ]
von Minckwitz 2009 -0.06 (0.18) 17.9 % 0.94 [ 0.66, 1.34 ]
Kaufman 2009 -0.18 (0.18) 17.9 % 0.84 [ 0.59, 1.19 ]
Slamon 2001 -0.22 (0.11) 48.0 % 0.80 [ 0.65, 1.00 ]
Total (95% CI) 100.0 % 0.82 [ 0.70, 0.95 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.05, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Efficacy of trastuzumab, Outcome 3 Overall survival - stratified by type of
regimen.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 3 Overall survival - stratified by type of regimen
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Taxane-containing regimen
Marty 2005 -0.32 (0.19) 14.8 % 0.73 [ 0.50, 1.05 ]
Slamon 2001 -0.18 (0.13) 31.5 % 0.84 [ 0.65, 1.08 ]
Subtotal (95% CI) 46.3 % 0.80 [ 0.65, 0.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.036)
2 Anthracycline-containing regimen
Slamon 2001 -0.22 (0.16) 20.8 % 0.80 [ 0.59, 1.10 ]
Subtotal (95% CI) 20.8 % 0.80 [ 0.59, 1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
3 Aromatase inhibitor-containing regimen
Kaufman 2009 -0.18 (0.18) 16.4 % 0.84 [ 0.59, 1.19 ]
Subtotal (95% CI) 16.4 % 0.84 [ 0.59, 1.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
4 Other
Blackwell 2010 -0.22 (0.18) 16.4 % 0.80 [ 0.56, 1.14 ]
Subtotal (95% CI) 16.4 % 0.80 [ 0.56, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 100.0 % 0.81 [ 0.70, 0.93 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.95 (P = 0.0031)
Test for subgroup differences: Chi2 = 0.05, df = 3 (P = 1.00), I2 =0.0%
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Analysis 1.4. Comparison 1 Efficacy of trastuzumab, Outcome 4 Overall survival - stratified by treatment
line.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 4 Overall survival - stratified by treatment line
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 First-line
Marty 2005 -0.32 (0.19) 13.6 % 0.73 [ 0.50, 1.05 ]
Kaufman 2009 -0.18 (0.18) 15.2 % 0.84 [ 0.59, 1.19 ]
Slamon 2001 -0.22 (0.11) 40.7 % 0.80 [ 0.65, 1.00 ]
Subtotal (95% CI) 69.6 % 0.79 [ 0.67, 0.94 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0061)
2 Beyond progression
Blackwell 2010 (1) -0.22 (0.18) 15.2 % 0.80 [ 0.56, 1.14 ]
von Minckwitz 2009 -0.06 (0.18) 15.2 % 0.94 [ 0.66, 1.34 ]
Subtotal (95% CI) 30.4 % 0.87 [ 0.68, 1.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 100.0 % 0.82 [ 0.71, 0.94 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.06, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.90 (P = 0.0038)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
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Analysis 1.5. Comparison 1 Efficacy of trastuzumab, Outcome 5 Progression-free survival - all studies.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 5 Progression-free survival - all studies
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Huober 2012 -0.4 (0.33) 3.7 % 0.67 [ 0.35, 1.28 ]
Gasparini 2006 -0.36 (0.26) 5.9 % 0.70 [ 0.42, 1.16 ]
von Minckwitz 2009 -0.38 (0.18) 11.6 % 0.68 [ 0.48, 0.97 ]
Marty 2005 -0.652 (0.168) 13.1 % 0.52 [ 0.37, 0.72 ]
Kaufman 2009 -0.46 (0.15) 16.0 % 0.63 [ 0.47, 0.85 ]
Blackwell 2010 -0.3 (0.12) 23.2 % 0.74 [ 0.59, 0.94 ]
Slamon 2001 -0.67 (0.11) 26.5 % 0.51 [ 0.41, 0.63 ]
Total (95% CI) 100.0 % 0.61 [ 0.54, 0.70 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 6.85, df = 6 (P = 0.33); I2 =12%
Test for overall effect: Z = 7.52 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Efficacy of trastuzumab, Outcome 6 Progression-free survival - excluding
Blackwell.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 6 Progression-free survival - excluding Blackwell
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Huober 2012 -0.4 (0.33) 4.2 % 0.67 [ 0.35, 1.28 ]
Gasparini 2006 -0.36 (0.26) 6.8 % 0.70 [ 0.42, 1.16 ]
von Minckwitz 2009 -0.38 (0.18) 14.2 % 0.68 [ 0.48, 0.97 ]
Marty 2005 -0.652 (0.168) 16.3 % 0.52 [ 0.37, 0.72 ]
Kaufman 2009 -0.46 (0.15) 20.4 % 0.63 [ 0.47, 0.85 ]
Slamon 2001 -0.67 (0.11) 38.0 % 0.51 [ 0.41, 0.63 ]
Total (95% CI) 100.0 % 0.58 [ 0.50, 0.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.55, df = 5 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 8.12 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Efficacy of trastuzumab, Outcome 7 Progression-free survival - stratified by
type of regimen.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 7 Progression-free survival - stratified by type of regimen
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Taxane-containing regimen
Gasparini 2006 -0.36 (0.26) 5.6 % 0.70 [ 0.42, 1.16 ]
Slamon 2001 -0.832 (0.252) 6.0 % 0.44 [ 0.27, 0.71 ]
Marty 2005 -0.652 (0.168) 11.7 % 0.52 [ 0.37, 0.72 ]
Subtotal (95% CI) 23.3 % 0.53 [ 0.42, 0.68 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.74, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 5.11 (P < 0.00001)
2 Anthracycline-containing regimen
Slamon 2001 -0.246 (0.075) 30.1 % 0.78 [ 0.68, 0.91 ]
Subtotal (95% CI) 30.1 % 0.78 [ 0.68, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.28 (P = 0.0010)
3 Aromatase inhibitor-containing regimen
Huober 2012 -0.4 (0.33) 3.7 % 0.67 [ 0.35, 1.28 ]
Kaufman 2009 -0.46 (0.15) 13.8 % 0.63 [ 0.47, 0.85 ]
Subtotal (95% CI) 17.5 % 0.64 [ 0.49, 0.83 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.29 (P = 0.00099)
4 Other
von Minckwitz 2009 -0.38 (0.18) 10.5 % 0.68 [ 0.48, 0.97 ]
Blackwell 2010 -0.3 (0.12) 18.7 % 0.74 [ 0.59, 0.94 ]
Subtotal (95% CI) 29.1 % 0.72 [ 0.59, 0.88 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.25 (P = 0.0011)
Total (95% CI) 100.0 % 0.67 [ 0.59, 0.77 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.56, df = 7 (P = 0.22); I2 =27%
Test for overall effect: Z = 6.00 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.66, df = 3 (P = 0.05), I2 =61%
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Analysis 1.8. Comparison 1 Efficacy of trastuzumab, Outcome 8 Progression-free survival - stratified by
treatment line.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 8 Progression-free survival - stratified by treatment line
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 First-line
Huober 2012 -0.4 (0.33) 3.7 % 0.67 [ 0.35, 1.28 ]
Gasparini 2006 -0.36 (0.26) 5.9 % 0.70 [ 0.42, 1.16 ]
Marty 2005 -0.652 (0.168) 13.1 % 0.52 [ 0.37, 0.72 ]
Kaufman 2009 -0.46 (0.15) 16.0 % 0.63 [ 0.47, 0.85 ]
Slamon 2001 -0.67 (0.11) 26.5 % 0.51 [ 0.41, 0.63 ]
Subtotal (95% CI) 65.2 % 0.56 [ 0.49, 0.65 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.51, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 7.90 (P < 0.00001)
2 Beyond progression
von Minckwitz 2009 -0.38 (0.18) 11.6 % 0.68 [ 0.48, 0.97 ]
Blackwell 2010 (1) -0.3 (0.12) 23.2 % 0.74 [ 0.59, 0.94 ]
Subtotal (95% CI) 34.8 % 0.72 [ 0.59, 0.88 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.25 (P = 0.0011)
Total (95% CI) 100.0 % 0.61 [ 0.54, 0.70 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 6.85, df = 6 (P = 0.33); I2 =12%
Test for overall effect: Z = 7.52 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.21, df = 1 (P = 0.04), I2 =76%
0.5 0.7 1 1.5 2
Favours trastuzumab Favours control
(1) Lapatinib-containing regimen
52Trastuzumab-containing regimens for metastatic breast cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.9. Comparison 1 Efficacy of trastuzumab, Outcome 9 Overall response rate - all studies.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 9 Overall response rate - all studies
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Huober 2012 7/26 4/31 1.6 % 2.09 [ 0.69, 6.35 ]
Kaufman 2009 15/74 5/73 2.1 % 2.96 [ 1.13, 7.72 ]
Blackwell 2010 15/146 10/145 3.3 % 1.49 [ 0.69, 3.21 ]
von Minckwitz 2009 37/77 20/74 10.0 % 1.78 [ 1.14, 2.76 ]
Marty 2005 56/92 32/94 18.3 % 1.79 [ 1.29, 2.48 ]
Gasparini 2006 45/60 33/58 27.1 % 1.32 [ 1.01, 1.72 ]
Slamon 2001 118/235 74/234 37.6 % 1.59 [ 1.26, 1.99 ]
Total (95% CI) 710 709 100.0 % 1.58 [ 1.38, 1.82 ]
Total events: 293 (Trastuzumab), 178 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.50, df = 6 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 6.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Efficacy of trastuzumab, Outcome 10 Overall response rate - stratified by type
of regimen.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 10 Overall response rate - stratified by type of regimen
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Taxane-containing regimen
Slamon 2001 38/92 16/96 9.6 % 2.48 [ 1.49, 4.12 ]
Marty 2005 56/92 32/94 18.6 % 1.79 [ 1.29, 2.48 ]
Gasparini 2006 45/60 33/58 23.6 % 1.32 [ 1.01, 1.72 ]
Subtotal (95% CI) 244 248 51.8 % 1.71 [ 1.23, 2.38 ]
Total events: 139 (Trastuzumab), 81 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 5.30, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 3.16 (P = 0.0016)
2 Anthracycline-containing regimen
Slamon 2001 80/143 58/138 26.1 % 1.33 [ 1.04, 1.70 ]
Subtotal (95% CI) 143 138 26.1 % 1.33 [ 1.04, 1.70 ]
Total events: 80 (Trastuzumab), 58 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.022)
3 Aromatase inhibitor-containing regimen
Huober 2012 7/26 4/31 2.3 % 2.09 [ 0.69, 6.35 ]
Kaufman 2009 15/74 5/73 3.1 % 2.96 [ 1.13, 7.72 ]
Subtotal (95% CI) 100 104 5.4 % 2.55 [ 1.23, 5.27 ]
Total events: 22 (Trastuzumab), 9 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.012)
4 Other
Blackwell 2010 15/146 10/145 4.7 % 1.49 [ 0.69, 3.21 ]
von Minckwitz 2009 37/77 20/74 12.0 % 1.78 [ 1.14, 2.76 ]
Subtotal (95% CI) 223 219 16.7 % 1.70 [ 1.16, 2.49 ]
Total events: 52 (Trastuzumab), 30 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0064)
Total (95% CI) 710 709 100.0 % 1.61 [ 1.35, 1.91 ]
Total events: 293 (Trastuzumab), 178 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.31, df = 7 (P = 0.23); I2 =25%
Test for overall effect: Z = 5.34 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.86, df = 3 (P = 0.28), I2 =22%
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Analysis 1.11. Comparison 1 Efficacy of trastuzumab, Outcome 11 Overall response rate - stratified by
treatment line.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 1 Efficacy of trastuzumab
Outcome: 11 Overall response rate - stratified by treatment line
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 First-line
Huober 2012 7/26 4/31 1.6 % 2.09 [ 0.69, 6.35 ]
Kaufman 2009 15/74 5/73 2.1 % 2.96 [ 1.13, 7.72 ]
Marty 2005 56/92 32/94 18.3 % 1.79 [ 1.29, 2.48 ]
Gasparini 2006 45/60 33/58 27.1 % 1.32 [ 1.01, 1.72 ]
Slamon 2001 118/235 74/234 37.6 % 1.59 [ 1.26, 1.99 ]
Subtotal (95% CI) 487 490 86.7 % 1.57 [ 1.34, 1.84 ]
Total events: 241 (Trastuzumab), 148 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.19, df = 4 (P = 0.38); I2 =5%
Test for overall effect: Z = 5.65 (P < 0.00001)
2 Beyond progression
Blackwell 2010 15/146 10/145 3.3 % 1.49 [ 0.69, 3.21 ]
von Minckwitz 2009 37/77 20/74 10.0 % 1.78 [ 1.14, 2.76 ]
Subtotal (95% CI) 223 219 13.3 % 1.70 [ 1.16, 2.49 ]
Total events: 52 (Trastuzumab), 30 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0064)
Total (95% CI) 710 709 100.0 % 1.58 [ 1.38, 1.82 ]
Total events: 293 (Trastuzumab), 178 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.50, df = 6 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 6.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.70), I2 =0.0%
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Analysis 2.1. Comparison 2 Cardiac toxicity of trastuzumab, Outcome 1 Congestive heart failure - all
studies.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 2 Cardiac toxicity of trastuzumab
Outcome: 1 Congestive heart failure - all studies
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
Huober 2012 0/26 0/31 Not estimable
Blackwell 2010 1/149 0/146 5.3 % 2.94 [ 0.20, 42.85 ]
Marty 2005 2/86 0/76 5.9 % 4.43 [ 0.35, 55.84 ]
von Minckwitz 2009 4/77 0/74 6.4 % 8.65 [ 0.76, 99.04 ]
Gasparini 2006 1/63 1/60 7.2 % 0.95 [ 0.09, 9.57 ]
Kaufman 2009 2/103 2/104 14.4 % 1.01 [ 0.20, 5.15 ]
Slamon 2001 25/234 5/230 60.8 % 4.91 [ 2.23, 10.84 ]
Total (0.0% CI) 738 721 100.0 % 3.49 [ 1.88, 6.47 ]
Total events: 35 (Trastuzumab), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.34, df = 5 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.33 (P = 0.00086)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Cardiac toxicity of trastuzumab, Outcome 2 Congestive heart failure -
stratified by type of regimen.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 2 Cardiac toxicity of trastuzumab
Outcome: 2 Congestive heart failure - stratified by type of regimen
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
1 Taxane-containing regimen
Gasparini 2006 1/63 1/60 7.2 % 0.95 [ 0.09, 9.57 ]
Marty 2005 2/86 0/76 6.0 % 4.43 [ 0.35, 55.84 ]
Slamon 2001 2/91 1/95 9.6 % 2.09 [ 0.28, 15.43 ]
Subtotal (0.0% CI) 240 231 22.8 % 1.98 [ 0.54, 7.26 ]
Total events: 5 (Trastuzumab), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
2 Anthracycline-containing regimen
Slamon 2001 23/143 4/135 50.9 % 5.43 [ 2.28, 12.94 ]
Subtotal (0.0% CI) 143 135 50.9 % 5.43 [ 2.28, 12.94 ]
Total events: 23 (Trastuzumab), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.20 (P = 0.0014)
3 Aromatase inhibitor-containing regimen
Huober 2012 0/26 0/31 Not estimable
Kaufman 2009 2/103 2/104 14.5 % 1.01 [ 0.20, 5.15 ]
Subtotal (0.0% CI) 129 135 14.5 % 1.01 [ 0.20, 5.15 ]
Total events: 2 (Trastuzumab), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
4 Other
Blackwell 2010 1/149 0/146 5.4 % 2.94 [ 0.20, 42.85 ]
von Minckwitz 2009 4/77 0/74 6.5 % 8.65 [ 0.76, 99.04 ]
Subtotal (0.0% CI) 226 220 11.8 % 5.31 [ 0.87, 32.20 ]
Total events: 5 (Trastuzumab), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Total (0.0% CI) 738 721 100.0 % 3.37 [ 1.81, 6.27 ]
Total events: 35 (Trastuzumab), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.71, df = 6 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0013)
Test for subgroup differences: Chi2 = 2.92, df = 3 (P = 0.40), I2 =0.0%
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Analysis 2.3. Comparison 2 Cardiac toxicity of trastuzumab, Outcome 3 Congestive heart failure -
stratified by treatment line.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 2 Cardiac toxicity of trastuzumab
Outcome: 3 Congestive heart failure - stratified by treatment line
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
1 First-line
Huober 2012 0/26 0/31 Not estimable
Marty 2005 2/86 0/76 5.9 % 4.43 [ 0.35, 55.84 ]
Gasparini 2006 1/63 1/60 7.2 % 0.95 [ 0.09, 9.57 ]
Kaufman 2009 2/103 2/104 14.4 % 1.01 [ 0.20, 5.15 ]
Slamon 2001 25/234 5/230 60.8 % 4.91 [ 2.23, 10.84 ]
Subtotal (0.0% CI) 512 501 88.3 % 3.30 [ 1.71, 6.37 ]
Total events: 30 (Trastuzumab), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.94, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
2 Beyond progression
Blackwell 2010 1/149 0/146 5.3 % 2.94 [ 0.20, 42.85 ]
von Minckwitz 2009 4/77 0/74 6.4 % 8.65 [ 0.76, 99.04 ]
Subtotal (0.0% CI) 226 220 11.7 % 5.31 [ 0.87, 32.20 ]
Total events: 5 (Trastuzumab), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Total (0.0% CI) 738 721 100.0 % 3.49 [ 1.88, 6.47 ]
Total events: 35 (Trastuzumab), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.34, df = 5 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.33 (P = 0.00086)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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Analysis 2.4. Comparison 2 Cardiac toxicity of trastuzumab, Outcome 4 Left ventricular ejection fraction
(LVEF) decline - all studies.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 2 Cardiac toxicity of trastuzumab
Outcome: 4 Left ventricular ejection fraction (LVEF) decline - all studies
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
Gasparini 2006 0/63 0/60 Not estimable
Kaufman 2009 1/103 0/104 4.7 % 3.03 [ 0.21, 44.02 ]
von Minckwitz 2009 1/77 0/74 4.7 % 2.88 [ 0.20, 41.77 ]
Blackwell 2010 10/149 3/146 29.7 % 3.27 [ 1.13, 9.48 ]
Marty 2005 16/86 6/76 60.9 % 2.36 [ 1.12, 4.96 ]
Total (0.0% CI) 478 460 100.0 % 2.65 [ 1.48, 4.74 ]
Total events: 28 (Trastuzumab), 9 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0057)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Cardiac toxicity of trastuzumab, Outcome 5 LVEF decline - stratified by type of
regimen.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 2 Cardiac toxicity of trastuzumab
Outcome: 5 LVEF decline - stratified by type of regimen
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
1 Taxane-containing regimen
Gasparini 2006 0/63 0/60 Not estimable
Marty 2005 16/86 6/76 60.9 % 2.36 [ 1.12, 4.96 ]
Subtotal (0.0% CI) 149 136 60.9 % 2.36 [ 1.12, 4.96 ]
Total events: 16 (Trastuzumab), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.058)
2 Aromatase inhibitor-containing regimen
Kaufman 2009 1/103 0/104 4.7 % 3.03 [ 0.21, 44.02 ]
Subtotal (0.0% CI) 103 104 4.7 % 3.03 [ 0.21, 44.02 ]
Total events: 1 (Trastuzumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 Other
von Minckwitz 2009 1/77 0/74 4.7 % 2.88 [ 0.20, 41.77 ]
Blackwell 2010 10/149 3/146 29.7 % 3.27 [ 1.13, 9.48 ]
Subtotal (0.0% CI) 226 220 34.4 % 3.21 [ 1.19, 8.64 ]
Total events: 11 (Trastuzumab), 3 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
Total (0.0% CI) 478 460 100.0 % 2.65 [ 1.48, 4.74 ]
Total events: 28 (Trastuzumab), 9 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0057)
Test for subgroup differences: Chi2 = 0.18, df = 2 (P = 0.92), I2 =0.0%
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Analysis 2.6. Comparison 2 Cardiac toxicity of trastuzumab, Outcome 6 LVEF decline - stratified by
treatment line.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 2 Cardiac toxicity of trastuzumab
Outcome: 6 LVEF decline - stratified by treatment line
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
1 First-line
Gasparini 2006 0/63 0/60 Not estimable
Kaufman 2009 1/103 0/104 4.7 % 3.03 [ 0.21, 44.02 ]
Marty 2005 16/86 6/76 60.9 % 2.36 [ 1.12, 4.96 ]
Subtotal (0.0% CI) 252 240 65.6 % 2.40 [ 1.17, 4.91 ]
Total events: 17 (Trastuzumab), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
2 Beyond progression
Blackwell 2010 10/149 3/146 29.7 % 3.27 [ 1.13, 9.48 ]
von Minckwitz 2009 1/77 0/74 4.7 % 2.88 [ 0.20, 41.77 ]
Subtotal (0.0% CI) 226 220 34.4 % 3.21 [ 1.19, 8.64 ]
Total events: 11 (Trastuzumab), 3 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
Total (0.0% CI) 478 460 100.0 % 2.65 [ 1.48, 4.74 ]
Total events: 28 (Trastuzumab), 9 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0057)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.69), I2 =0.0%
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Analysis 3.1. Comparison 3 Other toxicities, Outcome 1 Neutropenic fever - all studies.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 3 Other toxicities
Outcome: 1 Neutropenic fever - all studies
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
von Minckwitz 2009 2/77 0/74 3.4 % 4.81 [ 0.38, 60.61 ]
Gasparini 2006 1/63 1/60 4.2 % 0.95 [ 0.09, 9.57 ]
Marty 2005 21/92 16/94 92.4 % 1.34 [ 0.82, 2.19 ]
Total (0.0% CI) 232 228 100.0 % 1.38 [ 0.86, 2.21 ]
Total events: 24 (Trastuzumab), 17 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Other toxicities, Outcome 2 Neutropenic fever - stratified by type of regimen.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 3 Other toxicities
Outcome: 2 Neutropenic fever - stratified by type of regimen
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
1 Taxane-containing regimen
Gasparini 2006 1/63 1/60 4.2 % 0.95 [ 0.09, 9.57 ]
Marty 2005 21/92 16/94 92.4 % 1.34 [ 0.82, 2.19 ]
Subtotal (0.0% CI) 155 154 96.6 % 1.32 [ 0.82, 2.13 ]
Total events: 22 (Trastuzumab), 17 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Other
von Minckwitz 2009 2/77 0/74 3.4 % 4.81 [ 0.38, 60.61 ]
Subtotal (0.0% CI) 77 74 3.4 % 4.81 [ 0.38, 60.61 ]
Total events: 2 (Trastuzumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (0.0% CI) 232 228 100.0 % 1.38 [ 0.86, 2.21 ]
Total events: 24 (Trastuzumab), 17 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 0.68, df = 1 (P = 0.41), I2 =0.0%
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Analysis 3.3. Comparison 3 Other toxicities, Outcome 3 Neutropenic fever - stratified by treatment line.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 3 Other toxicities
Outcome: 3 Neutropenic fever - stratified by treatment line
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
1 First-line
Gasparini 2006 1/63 1/60 4.2 % 0.95 [ 0.09, 9.57 ]
Marty 2005 21/92 16/94 92.4 % 1.34 [ 0.82, 2.19 ]
Subtotal (0.0% CI) 155 154 96.6 % 1.32 [ 0.82, 2.13 ]
Total events: 22 (Trastuzumab), 17 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Beyond progression
von Minckwitz 2009 2/77 0/74 3.4 % 4.81 [ 0.38, 60.61 ]
Subtotal (0.0% CI) 77 74 3.4 % 4.81 [ 0.38, 60.61 ]
Total events: 2 (Trastuzumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (0.0% CI) 232 228 100.0 % 1.38 [ 0.86, 2.21 ]
Total events: 24 (Trastuzumab), 17 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 0.68, df = 1 (P = 0.41), I2 =0.0%
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Analysis 3.4. Comparison 3 Other toxicities, Outcome 4 Anaemia - all studies.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 3 Other toxicities
Outcome: 4 Anaemia - all studies
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
Gasparini 2006 0/63 0/60 Not estimable
von Minckwitz 2009 0/77 2/74 13.2 % 0.19 [ 0.02, 2.42 ]
Marty 2005 1/92 1/94 15.8 % 1.02 [ 0.10, 10.33 ]
Slamon 2001 5/234 4/230 71.0 % 1.23 [ 0.41, 3.66 ]
Total (0.0% CI) 466 458 100.0 % 0.93 [ 0.37, 2.35 ]
Total events: 6 (Trastuzumab), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Other toxicities, Outcome 5 Anaemia - stratified by type of regimen.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 3 Other toxicities
Outcome: 5 Anaemia - stratified by type of regimen
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
1 Taxane-containing regimen
Gasparini 2006 0/63 0/60 Not estimable
Marty 2005 1/92 1/94 15.8 % 1.02 [ 0.10, 10.33 ]
Slamon 2001 1/91 1/95 15.8 % 1.04 [ 0.10, 10.56 ]
Subtotal (0.0% CI) 246 249 31.7 % 1.03 [ 0.20, 5.30 ]
Total events: 2 (Trastuzumab), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
2 Anthracycline-containing regimen
Slamon 2001 4/143 3/135 55.1 % 1.26 [ 0.36, 4.35 ]
Subtotal (0.0% CI) 143 135 55.1 % 1.26 [ 0.36, 4.35 ]
Total events: 4 (Trastuzumab), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
3 Other
von Minckwitz 2009 0/77 2/74 13.2 % 0.19 [ 0.02, 2.42 ]
Subtotal (0.0% CI) 77 74 13.2 % 0.19 [ 0.02, 2.42 ]
Total events: 0 (Trastuzumab), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Total (0.0% CI) 466 458 100.0 % 0.92 [ 0.37, 2.32 ]
Total events: 6 (Trastuzumab), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 1.22, df = 2 (P = 0.54), I2 =0.0%
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Analysis 3.6. Comparison 3 Other toxicities, Outcome 6 Anaemia - stratified by treatment line.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 3 Other toxicities
Outcome: 6 Anaemia - stratified by treatment line
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
1 First-line
Gasparini 2006 0/63 0/60 Not estimable
Marty 2005 1/92 1/94 15.8 % 1.02 [ 0.10, 10.33 ]
Slamon 2001 5/234 4/230 71.0 % 1.23 [ 0.41, 3.66 ]
Subtotal (0.0% CI) 389 384 86.8 % 1.19 [ 0.44, 3.19 ]
Total events: 6 (Trastuzumab), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Beyond progression
von Minckwitz 2009 0/77 2/74 13.2 % 0.19 [ 0.02, 2.42 ]
Subtotal (0.0% CI) 77 74 13.2 % 0.19 [ 0.02, 2.42 ]
Total events: 0 (Trastuzumab), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Total (0.0% CI) 466 458 100.0 % 0.93 [ 0.37, 2.35 ]
Total events: 6 (Trastuzumab), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Chi2 = 1.21, df = 1 (P = 0.27), I2 =18%
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Analysis 3.7. Comparison 3 Other toxicities, Outcome 7 Neutropenia - all studies.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 3 Other toxicities
Outcome: 7 Neutropenia - all studies
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
von Minckwitz 2009 4/77 3/74 8.5 % 1.28 [ 0.38, 4.37 ]
Gasparini 2006 8/63 4/60 13.8 % 1.90 [ 0.73, 4.99 ]
Marty 2005 29/92 21/94 77.8 % 1.41 [ 0.94, 2.12 ]
Total (0.0% CI) 232 228 100.0 % 1.46 [ 1.02, 2.08 ]
Total events: 41 (Trastuzumab), 28 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Other toxicities, Outcome 8 Neutropenia - stratified by type of regimen.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 3 Other toxicities
Outcome: 8 Neutropenia - stratified by type of regimen
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
1 Taxane-containing regimen
Gasparini 2006 8/63 4/60 13.8 % 1.90 [ 0.73, 4.99 ]
Marty 2005 29/92 21/94 77.8 % 1.41 [ 0.94, 2.12 ]
Subtotal (0.0% CI) 155 154 91.5 % 1.48 [ 1.02, 2.14 ]
Total events: 37 (Trastuzumab), 25 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
2 Other
von Minckwitz 2009 4/77 3/74 8.5 % 1.28 [ 0.38, 4.37 ]
Subtotal (0.0% CI) 77 74 8.5 % 1.28 [ 0.38, 4.37 ]
Total events: 4 (Trastuzumab), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Total (0.0% CI) 232 228 100.0 % 1.46 [ 1.02, 2.08 ]
Total events: 41 (Trastuzumab), 28 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 3.9. Comparison 3 Other toxicities, Outcome 9 Neutropenia - stratified by treatment line.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 3 Other toxicities
Outcome: 9 Neutropenia - stratified by treatment line
Study or subgroup Trastuzumab Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,90% CI IV,Random,90% CI
1 First-line
Gasparini 2006 8/63 4/60 13.8 % 1.90 [ 0.73, 4.99 ]
Marty 2005 29/92 21/94 77.8 % 1.41 [ 0.94, 2.12 ]
Subtotal (0.0% CI) 155 154 91.5 % 1.48 [ 1.02, 2.14 ]
Total events: 37 (Trastuzumab), 25 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
2 Beyond progression
von Minckwitz 2009 4/77 3/74 8.5 % 1.28 [ 0.38, 4.37 ]
Subtotal (0.0% CI) 77 74 8.5 % 1.28 [ 0.38, 4.37 ]
Total events: 4 (Trastuzumab), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Total (0.0% CI) 232 228 100.0 % 1.46 [ 1.02, 2.08 ]
Total events: 41 (Trastuzumab), 28 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 4.1. Comparison 4 Sensitivity analysis: progression-free survival - by allocation concealment,
Outcome 1 Progression-free survival - by allocation concealment.
Review: Trastuzumab-containing regimens for metastatic breast cancer
Comparison: 4 Sensitivity analysis: progression-free survival - by allocation concealment
Outcome: 1 Progression-free survival - by allocation concealment
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Adequate
Gasparini 2006 -0.36 (0.26) 5.9 % 0.70 [ 0.42, 1.16 ]
Subtotal (95% CI) 5.9 % 0.70 [ 0.42, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
2 Unclear/inadequate
Huober 2012 -0.4 (0.33) 3.7 % 0.67 [ 0.35, 1.28 ]
von Minckwitz 2009 -0.38 (0.18) 11.6 % 0.68 [ 0.48, 0.97 ]
Marty 2005 -0.652 (0.168) 13.1 % 0.52 [ 0.37, 0.72 ]
Kaufman 2009 -0.46 (0.15) 16.0 % 0.63 [ 0.47, 0.85 ]
Blackwell 2010 -0.3 (0.12) 23.2 % 0.74 [ 0.59, 0.94 ]
Slamon 2001 -0.67 (0.11) 26.5 % 0.51 [ 0.41, 0.63 ]
Subtotal (95% CI) 94.1 % 0.61 [ 0.53, 0.70 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.59, df = 5 (P = 0.25); I2 =24%
Test for overall effect: Z = 6.83 (P < 0.00001)
Total (95% CI) 100.0 % 0.61 [ 0.54, 0.70 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 6.85, df = 6 (P = 0.33); I2 =12%
Test for overall effect: Z = 7.52 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.62), I2 =0.0%
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A P P E N D I C E S
Appendix 1. Cochrane Central Register of Controlled Trials (CENTRAL)
#1 MeSH descriptor: [Breast Neoplasms] explode all trees
#2 breast and (cancer* or tumour* or tumor* or neoplas*)
#3 #1 or #2
#4 (adverse or toxic or side) and (effect* or event* or drug reaction*)
#5 MeSH descriptor: [Drug Toxicity] explode all trees
#6 #4 or #5
#7 trastuzumab or herceptin
#8 #3 and #6 and #7
Appendix 2. MEDLINE search strategy (1966 to current) (OVID)
1 exp Breast Neoplasms/
2 breast.ab,ti,tw.
3 mammary.ab,ti,tw.
4 2 or 3
5 cancer*.ab,ti,tw.
6 carcinoma*.ab,ti,tw.
7 neoplas*.ab,ti,tw.
8 tumo?r*.ab,ti,tw.
9 metastas*.ab,ti,tw.
10 5 or 6 or 7 or 8 or 9
11 4 and 10
12 metastatic breast cancer.ab,ti,tw,kw.
13 advance* breast cancer.ab,ti,tw,kw.
14 1 or 11 or 12 or 13
15 trastuzumab.mp.
16 herceptin.mp.
17 15 or 16
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(Continued)
18 exp Antineoplastic Agents/ae, ct, de, to [Adverse Effects, Contraindications, Drug Effects, Toxicity]
19 exp Drug Hypersensitivity/
20 exp Drug Toxicity/
21 exp Drug Tolerance/
22 exp Causality/
23 exp Risk/
24 exp Product Surveillance, Postmarketing/
25 18 or 19 or 20 or 21 or 22 or 23 or 24
26 safe*.ab,ti.
27 adr.ab,ti.
28 adrs.ab,ti.
29 tolerabilit*.ab,ti.
30 toxicit*.ab,ti.
31 adverse reaction*.ab,ti.
32 hypersensitivit*.ab,ti.
33 adverse effect*.ab,ti.
34 undesirable effect*.ab,ti.
35 toxic effect*.ab,ti.
36 complication*.ab,ti.
37 causalit*.ab,ti.
38 risk*.ab,ti.
39 postmarketing.ab,ti.
40 post marketing.ab,ti.
41 side effect*.ab,ti.
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(Continued)
42 side event*.ab,ti.
43 side outcome*.ab,ti.
44 adverse event*.ab,ti.
45 adverse outcome*.ab,ti.
46 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45
47 25 or 46
48 14 and 17 and 47
49 limit 48 to (english language and humans and yr=“1996 -Current”)
Appendix 3. EMBASE (January 1996 to current) (host: Embase.com)
#23 #22 AND [humans]/lim AND [english]/lim AND [embase]/lim AND [1996-2013]/py
#22 #9 AND #20 AND #21
#21 #3 OR #6
#20 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #19
#19 #17 AND #18
#18 effect*:ab,ti OR event*:ab,ti OR outcome*:ab,ti
#17 side:ab,ti OR adverse:ab,ti
#16 safe*:ab,ti OR adr:ab,ti OR adrs:ab,ti OR tolerabilit*:ab,ti OR toxicit*:ab,ti OR undesirable:ab,ti AND effect*:ab,ti OR adverse:
ab,ti AND reaction*:ab,ti OR hypersensitivit*:ab,ti OR toxic:ab,ti AND effect*:ab,ti OR complication*:ab,ti OR causalit*:ab,ti OR
risk:ab,ti OR postmarketing:ab,ti OR post:ab,ti AND marketing:ab,ti
#15 ’postmarketing surveillance’/exp
#14 ’risk’/exp
#13 ’drug tolerance’/exp
#12 ’drug toxicity’/exp
#11 ’drug hypersensitivity’/exp
#10 ’antineoplastic agent’/exp/dd˙ae,dd˙to
#9 #7 OR #8
#8 trastuzumab:ab,ti OR herceptin:ab,ti
#7 ’trastuzumab’/exp
#6 #4 AND #5
#5 cancer*:ab,ti OR tumour*:ab,ti OR tumor*:ab,ti OR neoplasm*:ab,ti OR metastas*:ab,ti OR carcinoma*:ab,ti
#4 breast:ab,ti OR mammary:ab,ti OR mammaries:ab,ti
#3 #1 OR #2
#2 ’breast tumor’/exp
#1 ’breast cancer’/exp
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Appendix 4. WHO ICTRP search strategy
Basic search:
1. Trastuzumab containing regimens for metastatic breast cancer
2. Metastatic breast cancer AND trastuzumab
3. Advanced breast cancer AND trastuzumab
4. Metastatic breast cancer AND herceptin
5. Advanced breast cancer AND herceptin
Advanced search:
1. Title: Trastuzumab containing regimens for metastatic breast cancer
Recruitment Status: All
2. Condition: metastatic breast cancer
Intervention: trastuzumab OR herceptin OR trastuzumab containing regime*
Recruitment Status: All
3. Condition: advanced breast cancer
Intervention: trastuzumab OR herceptin OR trastuzumab containing regime*
Recruitment Status: All
Appendix 5. Clinicaltrials.gov
Basic search:
1. Trastuzumab containing regimens for metastatic breast cancer[ft1]
2. (metastatic breast cancer OR advanced breast cancer) AND (trastuzumab OR herceptin)[ft2]
Advanced search:
1. Title: Trastuzumab containing regimens for metastatic breast cancer
Recruitment: All studies
Study Results: All studies
Study Type: All studies
Gender: All studies
2. Condition: (metastatic breast cancer AND advanced breast cancer)
Intervention: trastuzumab OR herceptin OR trastuzumab containing regime*
Recruitment: All studies
Study Results: All studies
Study Type: All studies
Gender: All studies
Appendix 6. BIOSIS (January 1996 to current) (host: ISI Web of Knowledge)
# 7 #6 AND #5
Databases=BIOSIS Previews Timespan=1996-2013
# 6 #4 AND #3
Databases=BIOSIS Previews Timespan=1996-2013
# 5 #2 AND #1
Databases=BIOSIS Previews Timespan=1996-2013
75Trastuzumab-containing regimens for metastatic breast cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
# 4 (TS=(advanced breast cancer*) OR TS=(advanced breast neoplasm*) OR TS=(advanced breast tumor*) OR TS=(advanced
breast tumour*)) AND Language=(English) AND Taxa Notes=(Humans)
Databases=BIOSIS Previews Timespan=1996-2013
# 3 (TS=(metastatic breast cancer*) OR TS=(metastatic breast neoplasm*) OR TS=(metastatic breast tumor*) OR TS=(metastatic
breast tumour*)) AND Language=(English) AND Taxa Notes=(Humans)
Databases=BIOSIS Previews Timespan=1996-2013
# 2 (CC=(trastuzumab OR Toxicology - Pharmacology) OR CC=(herceptin OR Toxicology - Pharmacology)) AND Language=
(English) AND Taxa Notes=(Humans)
Databases=BIOSIS Previews Timespan=1996-2013
# 1 (MC=(trastuzumab OR Oncology) OR MC=(herceptin OR Oncology)) AND Language=(English) AND Taxa Notes=(Hu-
mans)
Databases=BIOSIS Previews Timespan=1996-2013
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Protocol
Intervention group: trastuzumab alone or in combination with chemotherapy.
Comparator: the same chemotherapy alone or no trastuzumab.
Review
Intervention group: trastuzumab alone or in combination with chemotherapy, hormonal therapy or targeted agents.
Comparator: the same regimen used in the intervention group without trastuzumab.
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